

2-hydroxyglutarate mediates whitening of brown adipocytes coupled to nuclear softening upon mitochondrial dysfunction

Received: 9 July 2024

Accepted: 12 June 2025

Published online: 1 August 2025

 Check for updates

Harshita Kaul^{1,2}, Lea Isermann^{1,2}, Katharina Senft^{1,2}, Milica Popovic^{1,2}, Theodoros Georgomanolis^{2,3}, Linda Baumann^{1,2}, Pujyanathan Sivanesan^{1,2}, Andromachi Pouikli^{2,3}, Hendrik Nolte⁴, Bojana Lucic⁵, Ximena Hildebrandt^{2,6,7}, Katrin Seidel², Thorsten Gnäd^{8,9}, Felix Gaedke², Ulrike Göbel², Franziska Peters¹⁰, Maksym Cherevatenko^{2,3}, Joo Hyun Park¹², Astrid Schauss², Nieves Peltzer^{2,6,7}, Jens Claus Brüning^{2,11}, Jan-Wilhelm Kornfeld¹², Alexander Pfeifer⁸, Thomas Langer^{2,4}, Marina Lusic⁵, Sara A. Wickström^{2,10,13}, Christian Frezza^{2,3,14} & Aleksandra Trifunovic^{1,2,7}✉

Mitochondria have a crucial role in regulating cellular homeostasis in response to intrinsic and extrinsic cues by changing cellular metabolism to meet these challenges. However, the molecular underpinnings of this regulation and the complete spectrum of these physiological outcomes remain largely unexplored. In this study, we elucidate the mechanisms driving the whitening phenotype in brown adipose tissue (BAT) deficient in the mitochondrial matrix protease CLPP. Here we show that CLPP-deficient BAT shows aberrant accumulation of lipid droplets, which occurs independently of defects in oxygen consumption and fatty acid oxidation. Our results indicate that mitochondrial dysfunction due to CLPP deficiency leads to the build-up of the oncometabolite D-2-hydroxyglutarate (D-2HG), which in turn promotes lipid droplet enlargement. We further demonstrate that D-2HG influences gene expression and decreases nuclear stiffness by modifying epigenetic signatures. We propose that lipid accumulation and altered nuclear stiffness regulated through 2HG are stress responses to mitochondrial dysfunction in BAT.

Mitochondria have traditionally been regarded as distinct cellular entities primarily responsible for energy production¹. However, increasing evidence shows that they are dynamic organelles that adapt to metabolic changes and cellular stress². Consequently, mitochondria maintain cellular homeostasis through communication with the nucleus and other organelles².

Given their fundamental role, it is not surprising that mitochondrial dysfunction, especially oxidative phosphorylation (OXPHOS) deficiency, is linked to ageing and many diseases³. Mitochondrial stress triggers nuclear responses that alter gene expression to counteract

cellular damage⁴. In mammalian cells, the mitochondrial integrated stress response (mitoISR) is one of the earliest transcriptional programmes activated by OXPHOS disruption⁵. This leads to metabolic reprogramming that can support or hinder tissue homeostasis^{6,7}.

The physiological consequences of mitochondrial stress remain incompletely understood, particularly in a tissue-specific context. White and brown adipose tissues (WAT and BAT) depend heavily on mitochondrial function and exhibit remarkable plasticity to meet physiological demands⁸. In WAT, mitochondria regulate energy storage and mobilization through triglyceride accumulation and




Fig. 1 | Loss of CLPP leads to cell-autonomous BAT whitening. **a**, Representative whole-BAT images from wild-type (WT), ubiquitously-CLPP-deficient mice (KO), adipose-specific CLPP-KO (AKO) mice or BAT-specific CLPP-KO (BKO) mice. **b**, LD size measurement from WT and CLPP-KO BAT. $n = 2,289$ LDs for WT and $n = 724$ LDs for KO. **c**, Representative transmission electron microscopy images of BAT tissue from WT and CLPP-KO mice. Scale bars, 50 μm , 5 μm and 0.5 μm (from top to bottom). **d, e**, Steady-state levels of OXPHOS supercomplexes (SC) in the BAT mitochondria of WT and CLPP-KO, CLPP-AKO and CLPP-BKO mice, analysed by blue native-PAGE followed by western blot for CI (NDUFA9) (**d**) and CV (ATP5A) (**e**) ($n = 3$). **f**, OCRs of whole BAT lysates from WT and CLPP-KO mice ($n = 3$). **g**, Numerical density of mitochondria in WT and CLPP-KO BAT ($n = 48$ fields per genotype obtained from three different mice from each genotype). **h**, Representative images of cultured and in-vitro-differentiated WT and

CLPP-KO mBA cells, stained with DAPI (nuclei) and Bodipy (LDs). Scale bars, 100 μm . Images represent results obtained from four independent experiments. **i**, Flow cytometry analysis of lipid accumulation (Bodipy) in WT and CLPP-KO mBA cells. Data represent one out of four performed experiments. **j, k**, OCRs (**j**) and ECARs (**k**) of WT and CLPP-KO preADs and mBAs ($n = 8$). **b**, Data are presented using Tukey's box plot with the middle line marking the median, and whiskers show variability within $1.5 \times \text{IQR}$. Anything beyond is an outlier presented as the individual value. **f, g, j, k**, Data are presented as mean $\pm$ s.d. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$, as determined by unpaired two-tailed Student's t -test in **b, g, j** and **k**, and one-way analysis of variance (ANOVA) with multiple comparisons in **f, i** and **k**, the statistical significance between WT and knockout cells of the same cell types were plotted either above (mBA cells) or below the graph lines (preAD). **a, h**, Schematics were created using Biorender.com.

lipolysis⁹. By contrast, BAT, rich in mitochondria, drives thermogenesis through uncoupling protein 1 (UCP1), which dissipates energy as heat, a process essential for neonatal and cold-induced thermoregulation¹⁰. Both tissues exhibit metabolic plasticity: WAT undergoes browning in response to cold, β -adrenergic stimulation, exercise or fasting, increasing mitochondrial content and uncoupling. Conversely, BAT whitening occurs under thermoneutrality, ageing or nutrient overload, leading to lipid accumulation and loss of thermogenic function¹¹.

Chronic exposure to thermoneutrality ($\sim 30^\circ\text{C}$) induces BAT whitening through PARKIN-mediated mitophagy and a ChREBP-driven shift toward fatty acid synthesis^{12,13}. Factors such as obesity, high-fat diets and ageing similarly promote BAT whitening, characterized by lipid accumulation, reduced vascularization and impaired thermogenesis^{14–16}. Genetic loss of lipolytic and oxidative enzymes (for example, ATGL and CPT2)^{17,18}, or key transcriptional regulators (for example, PGC-1 and PRDM16)^{19,20}, disrupts BAT differentiation and mitochondrial biogenesis, leading to whitening. Regardless of the underlying cause, a common hallmark is lipid-droplet expansion with reduced mitochondrial mass or function²¹. Consistently, loss of mitochondrial proteins essential for fusion (MFN2 and OPA1)^{22,23} or mitochondrial DNA (mtDNA) maintenance (TFAM)²⁴ also triggers BAT whitening. These findings highlight the central role of OXPHOS integrity in BAT homeostasis, although the underlying mechanisms that connect mitochondrial function to the homeostasis in BAT remain incompletely understood.

We have recently shown that the loss of the mitochondrial matrix protease CLPP has contrasting effects in adipose tissue: it enhances oxidative phosphorylation (OXPHOS) in WAT but impairs BAT thermogenesis and promotes lipid accumulation, consistent with a whitening phenotype²⁵. CLPP levels rise in BAT with cold exposure, unlike other mitochondrial proteases, but decline with ageing^{26,27}. In a deep BAT proteomics screen involving a cohort of 163 genetically defined diversity outbred mice, CLPP correlated strongly with UCP1 (<https://wren.hms.harvard.edu/opabat/>)²⁸. Furthermore, several of the identified UCP1 interactors are known CLPP substrates, supporting a strong link between CLPP and BAT function^{25,28,29}.

Here, we show that CLPP deficiency in BAT drives lipid droplet (LD) expansion through respiratory-chain dysfunction, independent of changes in oxygen consumption. This phenotype is driven by accumulation of D-2HG, an oncometabolite that alters chromatin and nuclear architecture. We reveal that mitochondrial dysfunction modulates epigenetic programmes, reducing nuclear stiffness and promoting BAT whitening. Together, our results uncover a previously unrecognized connection between mitochondrial function, metabolic signalling and chromatin reorganization in BAT. These insights shed light on how CLPP deficiency contributes to BAT whitening and

impaired thermogenic function, expanding our understanding of mitochondrial regulation in adipose tissue biology.

Results

CLPP loss in BAT causes mild dysfunction and whitening


To study the role of mitochondria in the physiological remodelling of BAT, we used a mouse model with deletion of the mitochondrial protease CLPP (*Clpp*^{-/-}, hereafter CLPP-KO), which is involved in OXPHOS complex synthesis and maintenance^{25,29}. The loss of CLPP in BAT led to the accumulation of fewer but larger LDs, giving the tissue a pale appearance consistent with BAT whitening (Fig. 1a–c). This phenotype was intrinsic to BAT and not due to systemic CLPP deficiency, because similar whitening was observed in tissue-specific knockouts, including pan-adipose (CLPP-AKO: *Clpp*^{fl/fl}; *Adipoq-cre*)³⁰ and brown-fat-specific models (CLPP-BKO: *Clpp*^{fl/fl}; *Ucp1-cre*)³¹ (Fig. 1a and Extended Data Fig. 1a,b). Although whole-body CLPP deletion resulted in significant weight loss, CLPP-AKO mice maintained normal body size, and CLPP-BKO mice exhibited only mild weight reductions that were more pronounced in males (Extended Data Fig. 1c). Although male and female mice exhibit naturally different weight trajectories as they age, our extensive experience with CLPP-deficient models suggests that these differences do not categorically impact study outcomes. Therefore, we combined data from both sexes in subsequent analyses, ensuring balanced representation of male and female mice across all experiments whenever feasible.

In addition to enlarged LDs, ultrastructural analysis revealed increased numbers of enlarged mitochondria in CLPP-KO BAT, some of which were visibly paler with fewer cristae, suggesting impaired OXPHOS function (Fig. 1b–c). Mitochondria isolated from CLPP-KO, CLPP-AKO and CLPP-BKO BAT exhibited reduced levels of respiratory complex I (CI) and CI-containing supercomplexes, accompanied by decreased CI activity (Fig. 1d and Extended Data Fig. 1d). Consistent with this, CLPP-KO BAT showed accumulation of F1 subassemblies of complex V (CV), which are essential for maintaining membrane potential when OXPHOS is compromised (Fig. 1e and Extended Data Fig. 1e).

Knockout tissue homogenates displayed reduced lipolysis, becoming significant after forskolin stimulation, suggesting that impaired lipolytic activation (glycerol release) could contribute to the whitening phenotype (Extended Data Fig. 1f). Despite these mitochondrial defects, oxygen-consumption rates (OCRs) in BAT lysates remained unchanged under both basal and stimulated conditions (Fig. 1f), probably owing to compensatory mitochondrial biogenesis (Fig. 1g). By contrast, thermoneutrality-induced whitening involves mitophagy¹⁵, whereas high-fat-diet-driven whitening causes LD accumulation without changes in mitochondrial content¹⁶. These findings point to distinct mitochondrial responses in different BAT whitening contexts and LD expansions.

Fig. 2 | BAT is remodelled at multiple levels following CLPP loss. **a**, Left, volcano plots of differentially expressed genes in BAT isolated from CLPP-KO, CLPP-AKO or CLPP-BKO mice, compared with the WT ($n = 4$). Coloured dots show significantly changed transcripts ($P \leq 0.01$, two-fold-change). Right, Gene Ontology: Biological Process (GO:BP) analysis of shared significantly changed transcripts (in RNA-seq analysis) in BAT from CLPP-KO, CLPP-AKO and CLPP-BKO mice (Supplementary Table 3). **b**, Representative H&E staining of BAT from STING-deficient (STING-KO) or STING- and CLPP-deficient (STING/CLPP DKO) mice. Scale bars, 200 μm (results obtained from three mice per genotype). **c,d**, GSEA enrichment plots for gene signatures related to angiogenesis and actin cytoskeleton (**c**) and brown-fat differentiation and myogenesis (**d**). **e**, Heat map with relative Z-scores of significantly changed proteins ($P \leq 0.05$) in SVF from WT and CLPP-KO mice. **f**, GSEA enrichment plots for gene signatures related to mitochondrial function. **g**, Top, heat map showing relative Z-scores of ATF4-target genes in the transcriptome dataset from BAT tissue of CLPP-BKO mice compared with those in WT mice. Bottom, GSEA enrichment plots for ATF4-target gene signatures. **h**, GSEA enrichment plots for gene signatures related to

lipid metabolism. **i**, Venn diagram depicting overlapping and unique changes in significantly changed transcripts ($P \leq 0.05$) in CLPP-BKO BAT compared with changes in mice housed at 4°C and those initially housed at 4°C for 1 week and subsequently moved to thermoneutrality (30°C) for 4 weeks (rewarm versus cold)³⁵ and LSD1-KO mice³⁶ (Supplementary Table 2). **j**, GO:BP analysis of common significantly changed BAT proteins ($P \leq 0.05$) from CLPP-KO, CLPP-AKO and CLPP-BKO mice (Supplementary Table 3). **k**, Average changes of individual OXPHOS complexes isolated from CLPP-KO cytoplasmic mitochondria (CM) or the whole BAT tissue lysate (WTL). Each data point represents average fold change value (CLPP-KO/WT, $n = 4$) of individual OXPHOS subunits obtained from proteomics analyses (Supplementary Tables 3 and 4). The number of individual OXPHOS complex subunits identified in proteomics determines n ($n = 40$ (CI); $n = 4$ (CII); $n = 7$ (CIII); $n = 11$ (CIV); $n = 14$ (CV)). Data are presented as mean $\pm$ s.d. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$ as determined by paired two-tailed Student's *t*-test. **a,j**, The size of the dots represents the number of genes and the colour of the dots represent the adjusted *P* values.



To explore the underlying mechanisms, we established immortalized preadipocyte (preAD) cultures from CLPP wild-type and knockout BAT (Fig. 1h). Upon differentiation, these cells exhibited mature brown adipocyte (mBA) features, including multilocular LDs and oligomycin resistance, indicative of mitochondrial uncoupling (Fig. 1h–k and Extended Data Fig. 1g). Both wild-type and CLPP-KO mBAs strongly upregulated UCP1 (Extended Data Fig. 1h). Transcript levels of LD-associated proteins were markedly higher in CLPP-KO mBAs, including the ubiquitous marker PLIN2 (also known as ADRP) and the adipocyte-specific proteins PLIN1 and PLIN4 (Extended Data Fig. 1h).

OCR and extracellular acidification rate (ECAR) measurements in mBAs revealed minimal, if any, difference between wild-type and CLPP-KO cells (Fig. 1j,k). However, both basal OCR and ECAR were higher than those in preADs, reflecting increased metabolic activity upon differentiation. These results confirm that mBAs faithfully model adult brown adipocyte function in both wild-type and CLPP-deficient conditions.

Multimodal analyses reveal tissue-autonomous BAT remodelling

To investigate the global impact of CLPP loss in BAT, we first analysed gene expression across all CLPP-deficient models (Fig. 2a). Gene Ontology (GO) enrichment using DAVID³² identified 707 commonly upregulated and 639 downregulated transcripts shared across genotypes (Supplementary Table 1). Inflammatory and immune pathways were among the most enriched (Fig. 2a and Supplementary Table 1), consistent with prior reports linking CLPP deficiency to cGAS–STING-mediated interferon-stimulated gene activation through mtDNA release³³. However, STING deletion in CLPP-KO mice did not alter the BAT whitening phenotype (Fig. 2b), and we observed neither immune infiltration in CLPP-BKO BAT nor immune progenitor expansion in bone marrow (Extended Data Fig. 2a,b). Cell-type deconvolution based on single-cell transcriptomic references³⁴ confirmed no major changes in cell composition, including immune populations (Extended Data Fig. 2c,d).

Beyond inflammation, CLPP-deficient BAT showed upregulation of pathways related to transcriptional regulation, signal transduction, adhesion, migration, cell death and lipid metabolism (Fig. 2a and Supplementary Table 1). Gene set enrichment analysis (GSEA) revealed enrichment of BAT-whitening-associated pathways such as actin remodelling and angiogenesis^{13,14} (Fig. 2a,c), whereas signatures of brown-adipocyte differentiation were negatively enriched and myogenesis appeared dysregulated (Fig. 2d), suggesting a possible impairment in BAT identity. Given the shared developmental origin of BAT and skeletal muscle, we tested whether differentiation was compromised by isolating the stromal vascular fraction (SVF) from wild-type and CLPP-KO BAT. Whole-proteome analysis of CLPP-BKO SVF revealed only minor changes, primarily in mitochondrial metabolism, mtDNA expression and OXPHOS proteins, with no alterations in markers of brown adipocytes or muscle differentiation (Fig. 2e), suggesting that early BAT development is intact.

Downregulated transcripts prominently included mitochondrial OXPHOS components and subunits of mitochondrial ribosomes (Fig. 2a,f), indicating organelle dysfunction. In agreement, the mitochondrial integrated stress response (mitoISR) was activated across models, as shown by GSEA and increased expression of ATF4 targets in CLPP-BKO BAT (Fig. 2g). Levels of transcripts involved in lipid metabolism, both catabolic (fatty acid oxidation) and anabolic (fatty acid and cholesterol synthesis), were also significantly reduced (Fig. 2a and Supplementary Table 1). Although GSEA confirmed overall suppression of lipid metabolic pathways, a subset of lipid-related genes was positively enriched, reflecting a dynamic remodelling process (Fig. 2h). This metabolic adaptation likely underlies LD accumulation, given that the OCR remained largely normal in knockout mBA cells (Fig. 1j), ruling out low OXPHOS activity as the cause.

We next compared CLPP-BKO transcriptomes with two BAT whitening models: thermoneutral exposure³⁵ and lysine-specific demethylase 1 (LSD1) BAT-specific knockout (LSD1-BKO) mice³⁶. Exposure to thermoneutrality more robustly altered BAT gene expression than did the loss of either CLPP or LSD1; in both of the latter models, less than quarter of alterations were unique (Fig. 2i). About 30% of the differentially expressed genes in CLPP-BKO mice overlapped with both whitening models (Fig. 2i and Extended Data Fig. 2e). GO terms shared across the three models matched those enriched in CLPP-deficient BAT (Supplementary Tables 1 and 2). Notably, *Clpp* expression was reduced in all three models, underscoring its link to BAT homeostasis (Extended Data Fig. 2e).

Although proteomic changes were less extensive than transcriptomic ones, with 116 upregulated and 66 downregulated proteins shared across CLPP-KO, CLPP-AKO and CLPP-BKO BAT, they largely mirrored transcript-level trends (Supplementary Table 3). GO analysis showed enrichment for mitochondrial proteins in both directions (Fig. 2j and Extended Data Fig. 3a). OXPHOS changes were modest, except for upregulated ATP synthase (complex V), consistent with a shift toward ATP production and reduced uncoupling, as seen in whitening BAT (Fig. 2k). Downregulated proteins clustered around fatty-acid-metabolism pathways, consistent with transcriptomic data (Fig. 2j).

To refine our analysis, we examined the proteomes of cytoplasmic mitochondria and peri-lipid droplet mitochondria (PDMs) from BAT³⁷. These mitochondrial populations had distinct yet overlapping profiles, and both showed clear OXPHOS alterations under CLPP deficiency (Extended Data Fig. 3b,c). Notably, both cytoplasmic mitochondria and PDMs displayed pronounced complex I and milder complex IV deficiencies, similar to heart mitochondria in CLPP-KO mice (Fig. 2k and Extended Data Fig. 3d). These functional impairments were not apparent at the tissue level, likely owing to increased mitochondrial biogenesis (Fig. 2k).

Collectively, these findings suggest that BAT whitening in CLPP-deficient mice is not driven by impaired differentiation or adipocyte-to-myocyte conversion, nor is it a direct consequence of OXPHOS loss. Instead, a transcriptional signature of suppressed lipid metabolism likely underlies the expansion of lipid droplets. The broad reshaping of the BAT transcriptome, particularly enrichment of GO terms related to transcriptional control and chromatin regulation, points to an adaptive stress response to CLPP loss (Fig. 2a and Supplementary Table 1).

CLPP loss causes D-2HG accumulation that dictates whitening

Transcriptome and proteome analyses of CLPP-deficient BAT revealed extensive metabolic adaptations. To further examine this, we performed semi-targeted metabolomics across CLPP-deficient models. Despite there being relatively few metabolites with significantly altered levels, a consistent overlap was observed between models (Fig. 3a and Supplementary Table 5). In line with the larger lipid droplets, levels of long-chain fatty acids were elevated, and levels of carnitines derived from branched-chain amino acids were dysregulated (Supplementary Table 5). Among all changed metabolites, 2-hydroxyglutarate (2HG) was the most strongly upregulated, showing a 2.7- to 3.7-fold increase across all three models (Fig. 3a,b). CLPP-deficient mBA cells also accumulated and secreted 2HG, suggesting a potential paracrine role (Fig. 3c and Extended Data Fig. 4a), whereas KO preADs did not, indicating that 2HG accumulation is specific to mature brown adipocytes (Fig. 3d).

2HG, a structural analogue of α -ketoglutarate (α -KG), exists as two enantiomers, D- and L-2HG. It can be produced at low levels by malate dehydrogenase (MDH)³⁸, lactate dehydrogenase A (LDHA)³⁹, phosphoglycerate dehydrogenase (PHGDH)⁴⁰ or mutant forms of isocitrate dehydrogenase (IDH1 and IDH2)⁴¹. To identify the source of 2HG, we analysed the expression of all known enzymes involved in its production^{38–41}. PHGDH was the only one that was




Fig. 3 | D-2HG accumulates in CLPP-deficient adipocytes. a, Volcano plots of metabolites with significantly changed levels in BAT isolated from ubiquitously deficient (KO), adipose-specific (AKO) or BAT-specific (BKO) CLPP-KO mice, compared with the WT ($n = 5$); dark colored dots present significantly changed metabolites ($P \leq 0.01$, two-fold-change) (as seen in Supplementary Table 5). **b–d**, 2HG levels in BAT tissue from WT and CLPP-KO, CLPP-AKO and CLPP-BKO mice ($n = 10$) (**b**); in WT and CLPP-KO mBA cells (left) and released in media by cultured cells (right), ($n = 5$) (**c**); and in WT and CLPP-KO preADs ($n = 5$). a.u., arbitrary units. **e**, Relative changes of proteins implicated in production of 2HG, measured in BAT tissue proteomics from CLPP-KO, CLPP-AKO and CLPP-BKO

mice compared with levels in WT mice ($n = 4$). **f**, Schematic depicting specific roles of PHGDH and the inhibition by NCT503. TCA, tricarboxylic acid cycle. **g**, Relative percentages of the D and L isoforms of 2HG in WT, and CLPP-KO, CLPP-AKO and CLPP-BKO BAT tissue, as assessed by the derivatization of 2HG using TSCP ($n = 5$). **a–g**, Each dataset represents either a single mouse or single cell culture plate. **b–e**, Data are presented as mean $\pm$ s.d. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$, as determined by unpaired two-tailed Student's *t*-test in **c–e** and **g** and one-way ANOVA with multiple comparisons in **b**. The schematic in **f** was created using Biorender.com.




Fig. 4 | D-2HG accumulation in adipocytes upon CLPP loss causes whitening.

a, 2HG levels as determined by targeted metabolomics in WT, CLPP-KO and NCT503-treated KO mBA cells ($n = 5$). **b**, Representative images of WT, CLPP-KO, D-2HG-treated WT and NCT503-treated CLPP-KO mBA cells, stained with DAPI (nucleus) and Bodipy (LDs). Scale bar, 100 μm (images represent results from four independent experiments). **c**, Lipid levels in NCT503-treated and untreated CLPP-KO mBA cells, normalized to the average MFI value of WT cells ($n = 12$). **d**, 2HG levels in WT and CLPP-KO BAT after 14 days of NCT503 treatment in vivo ($n = 12$ for WT, $n = 7$ for KO and $n = 11$ for KO + NCT). **e**, Top, representative images of whole BAT. Bottom, H&E staining of tissue from WT, CLPP-KO and

NCT503-treated KO (KO + NCT) mice. Scale bars, 200 μm . Images represent results from four mice per condition. **f**, Lipid levels in D-2HG-treated and untreated WT mBA cells, normalized to the average MFI value of WT cells ($n = 12$). MFI quantification of Bodipy-stained 2HG-treated and untreated WT mBA cells, normalized to the average of the MFI value of the WT cells ($n = 5$ per condition). Individual data points represent either a single mouse or a single cell culture plate. Data are presented as mean $\pm$ s.d. $^{**}P < 0.01$, $^{***}P < 0.001$, $^{****}P < 0.0001$, as determined by unpaired two-tailed Student's *t*-test in **c** and **f** and one-way ANOVA with multiple comparisons in **a** and **d**.

consistently upregulated, with more than fivefold increases across all CLPP-deficient models (Fig. 3e and Extended Data Fig. 4b). PHGDH catalyses the first step of the serine biosynthesis pathway, frequently induced as part of mitoISR in response to OXPHOS dysfunction (Fig. 3f)⁶. Although PHGDH protein was not increased in CLPP-KO mBA cells, its enzymatic activity was significantly increased (Extended Data Fig. 4c,d). Enantiomer-specific analysis confirmed that D-2HG is the predominant form in all CLPP-KO BAT samples, as well as in isolated mature CLPP-KO brown adipocytes (Fig. 3g and Extended Data Fig. 4e), aligning with known PHGDH promiscuity toward D-2HG production⁴⁰. The difference in 2HG enantiomer proportions between wild-type BAT and wild-type mBA cells is likely due to the heterogeneous nature of BAT, which consists of a mix of diverse cell types³⁴.

To directly test the putative role of PHGDH in D-2HG production, we inhibited it using NCT503, a selective inhibitor that blocks serine synthesis⁴². NCT503 treatment abolished 2HG accumulation in knockout mBA cells (Fig. 4a and Supplementary Table 6) and broadly altered metabolic pathways, including one-carbon metabolism, the SAM cycle and purine biosynthesis (Supplementary Table 6). Notably, PHGDH inhibition also reversed the whitening phenotype: lipid content was reduced, and smaller LDs formed in KO mBA cells, confirmed by fluorescence-activated cell sorting (Fig. 4b,c). Furthermore, two weeks of in vivo treatment with NCT503 normalized 2HG levels and reversed BAT whitening in CLPP-KO mice (Fig. 4d,e). To further probe the role of D-2HG, we overexpressed D-2HG dehydrogenase (D-2HGDH), the enzyme responsible for its degradation, in




Fig. 5 | CLPP loss mirrors D-2HG-induced histone methylation. a, Heatmap and coverage plots of H3K4me3 ChIP-seq in WT, CLPP-KO and 2HG-treated WT mBA cells, ± 2 kb around the transcription start site (TSS) ($n = 4$). **b**, Upset plot depicting the shared and unique H3K4me3 signatures between WT, CLPP-KO and D-2HG treated WT mBA cells (WT + 2HG). **c**, GO:BP analysis of H3K4me3 chromatin marks shared between KO and D-2HG-treated WT mBA cells (Supplementary Table 7). The size of the dots represent the number of genes, and the colour of the dots represent the adjusted P values ($n = 4$). Neg. reg., negative regulation; pos. reg., positive regulation; Pol II, RNA polymerase II.

d, Integrative Genomics Viewer browser views showing H3K4me3 read density on the promoters of selected genes ($n = 4$). **e**, Venn diagram depicting the number of unique and overlapping changes between transcripts differentially expressed in CLPP-KO mice, compared with distinct H3K4me3 signatures found in KO and D-2HG-treated WT mBA cells. **f**, GO:BP analysis of common significantly changed transcripts between CLPP-KO and D-2HG-treated WT mBA cells (Supplementary Table 8). The size of the dots represent the number of genes and the colour of the dots represent the adjusted P values ($n = 4$).

CLPP-deficient mBA cells. This significantly reduced D-2HG levels and partially reversed the whitening phenotype (Extended Data Fig. 4f,g). By contrast, inhibition of the ISR using ISRIB suppressed some ATF4 targets but had no effect on D-2HG accumulation or lipid storage (Extended Data Fig. 4h–j), suggesting that mitoISR is not the main driver of whitening phenotype following CLPP deficiency. Finally, we treated wild-type mBA cells with cell-permeable D-2HG (octyl D-2HG). This was sufficient to induce LD enlargement (Fig. 4b,f), directly linking D-2HG accumulation with BAT whitening.

In summary, our data demonstrate that CLPP loss activates PHGDH, leading to D-2HG accumulation in mature brown adipocytes. This metabolite contributes to lipid-droplet expansion and BAT whitening, revealing a critical role for aberrant serine metabolism and D-2HG in mediating the phenotypic consequences of mitochondrial stress.

CLPP loss and D-2HG treatment alter histone methylation

Elevated 2HG levels in cancer inhibit α -KG-dependent dioxygenases, affecting histone and DNA demethylation and leading to broad epigenetic reprogramming⁴³. Initial western blot analyses of CLPP-deficient cells and wild-type cells treated with D-2HG did not reveal consistent changes in key histone modifications (histone H3 dimethylated at Lys9 (H3K9me2), H3 trimethylated at Lys36 (H3K36me3), H3K4me3, H3K27me3) (Extended Data Fig. 5a). Given the limited sensitivity of this method, subtle epigenetic shifts might have been missed. Immunofluorescence assays showed modest, inconsistent changes in H3K9me2 and H3K27me3 (Extended Data Fig. 5b), prompting a more focused analysis of H3K4me3, a mark of active and poised promoters known to be influenced by 2HG⁴³.

Chromatin immunoprecipitation followed by high-throughput sequencing (ChIP-seq) revealed a global increase in H3K4me3 in both CLPP-deficient and D-2HG-treated mBA cells, with most enrichment occurring at promoter regions (Fig. 5a and Extended Data Fig. 5c,d). Notably, 1,141 out of 2,017 unique H3K4me3 peaks in CLPP-deficient cells overlapped with those in D-2HG-treated cells, suggesting a shared mechanism (Fig. 5b and Supplementary Table 7). GO analysis of these enriched loci shared between CLPP-deficient and D-2HG-treated mBA cells revealed biological processes associated with transcriptional regulation, differentiation, chromatin reorganization, lipid metabolism, apoptosis and DNA repair (Fig. 5c and Supplementary Table 7). Many of these categories also emerged in transcriptomic analyses of CLPP-deficient BAT (Supplementary Table 1), supporting their functional relevance.

A closer examination of individual genes identified increased H3K4me3 at promoters of key adipogenic regulators, including SREBP1 and SREBP2 (cholesterol and fatty acid metabolism), and C/EBP β (white adipocyte differentiation)^{44,45} (Fig. 5d). These changes suggest that D-2HG-induced chromatin remodelling could promote transcriptional programmes linked to adipogenesis and metabolism. To further explore this, we compared transcriptomes of CLPP-KO and D-2HG-treated mBA cells. More than 50% of significantly altered transcripts in CLPP-KO cells exhibited corresponding changes in H3K4me3 levels (Fig. 5e and Supplementary Tables 7 and 8). Additionally, more than one-third of these were shared with D-2HG-treated cells, implicating 2HG as a major driver of transcriptional changes in CLPP deficiency.

GO analysis revealed enrichment of both up- and downregulated transcripts in pathways related to chromatin remodelling, transcriptional and translational regulation and apoptosis, indicating broad alterations in these processes (Fig. 5f and Supplementary Table 8). Distinct trends were also evident: oxidative stress and DNA-damage-response terms were enriched among upregulated genes, whereas cell adhesion and extracellular matrix organization terms were downregulated in both models (Fig. 5f and Supplementary Table 8).

GSEA analysis identified substantial changes of lipid and fatty acid metabolism, mirroring alterations observed in CLPP-deficient

tissues (Figs. 2h and 6a). Among the transcripts upregulated in both CLPP-KO mBA cells and cells treated with D-2HG, we identified multiple enzymes involved in lipid metabolism, along with a variety of lipid transporters, including the highly upregulated CD36, a major regulator of fatty acid uptake in adipocytes and a key factor in LD growth⁴⁶ (Fig. 6b and Extended Data Fig. 5e). Many of these transcripts were suppressed in cells overexpressing D-2HGDH (Fig. 6c). In parallel, transcripts encoding adipogenic regulators, such as *Pparg* and *Cebpb*, were upregulated in both CLPP-KO mBA cells and cells treated with D-2HG. By contrast, *Ppargc1a*, encoding PGC1 α , was specifically induced in CLPP-deficient cells, consistent with underlying mitochondrial OXPHOS dysfunction (Fig. 6d). Remarkably, *Cebpa* expression appeared to be similarly influenced by mitochondrial dysfunction rather than D-2HG treatment (Fig. 6d). Conversely, cholesterol-biosynthesis genes were negatively enriched in both CLPP-deficient and D-2HG-treated cells; this change was also observed in BAT from all three CLPP-KO models (Extended Data Fig. 5f), highlighting a strong similarity between cells and tissues. Transcripts encoding SREBP1 and 2 (*Srebfl*, *Srebf2*) and their targets, including *Hmgcr* and *Hmgcs1*, which encode key catalysts of the initial rate-limiting steps of cholesterol biosynthesis (Fig. 6e). These changes coincided with reduced cellular cholesterol levels in both CLPP-deficient and D-2HG-treated cells, similar to the effect of simvastatin, an inhibitor of cholesterol biosynthesis (Fig. 6f).

Together, these findings demonstrate that CLPP deficiency and D-2HG treatment induce similar changes in transcriptome and epigenome, that converge on chromatin regulation, adipogenic signalling and cholesterol metabolism, linking mitochondrial dysfunction to coordinated metabolic reprogramming.

D-2HG mediates nuclear softening in CLPP-KO brown adipocytes

GO enrichment analysis of transcriptional and H3K4me3 ChIP-seq changes in CLPP-deficient tissues and cells consistently identified terms related to cell adhesion, migration, actin cytoskeleton organization and transcriptional regulation (Figs. 2a and 5c,f and Supplementary Tables 1, 7 and 8). A major number of enriched transcripts mapped to the nucleus, nucleoplasm and perinuclear cytoplasm. This aligns with emerging evidence linking nuclear architecture to cellular stress responses. The overlap of nucleus-related transcripts between CLPP-KO and D-2HG-treated cells supports this connection (Extended Data Fig. 6a). GSEA further revealed strong negative enrichment of nuclear envelope-associated transcripts in CLPP-deficient BAT, closely matching the transcriptomic signature of D-2HG-treated cells (Extended Data Fig. 6b), suggesting that metabolic perturbations could influence nuclear and cellular morphology.

We next explored the link between D-2HG, epigenetic changes and nuclear phenotype. Ultrastructural analyses revealed pronounced nuclear deformation in CLPP-deficient brown adipocytes, characterized by mitochondria clustering near and indenting the nuclear envelope (Fig. 7a). The extent of mito-nuclear interactions in CLPP-deficient BAT could be further observed in a high-resolution three-dimensional (3D) reconstituted model using serial section array tomography (Fig. 7b and Supplementary Video 1). Although direct contact sites with shared membranes were not detected, the two membranes were closely positioned with very little intercalated ER (Extended Data Fig. 6c,d and Supplementary Video 2).

Quantification of mito-nuclear indentations revealed an increase from -1.3 per nucleus in wild-type to -2.9 in CLPP-deficient cells, with some nuclei displaying up to 10 invaginations (Fig. 7c), indicating that nuclear mechanics were altered. Using atomic force microscopy (AFM), we detected a significant reduction in nuclear stiffness in CLPP-deficient adipocytes, mimicked by D-2HG treatment of wild-type cells (Fig. 7d,e). Inhibition of PHGDH with NCT503, which lowers D-2HG levels, restored




Fig. 6 | CLPP loss and D-2HG reshape lipid metabolic pathways. a, GSEA enrichment plots for gene signatures related to lipid metabolism shared between CLPP-KO cells and WT mBA cells treated with D-2HG. **b**, Relative mRNA levels of genes under GO:BP analysis term ‘Lipid metabolism’ enriched in CLPP-KO cells and WT cells treated with D-2HG, obtained from RNA sequencing (RNA-seq) analysis ($n = 4$) (Supplementary Table 8). **c**, Relative mRNA levels of genes involved in lipid metabolism in CLPP-KO cells upon expression of D-2HGDH, as measured by quantitative real-time PCR. Untreated WT cells, and cells treated with D-2HG, were used as controls ($n = 6$). **d**, Relative mRNA levels of major

regulators of lipogenesis genes enriched in CLPP-KO cells and WT cells treated with D-2HG obtained from RNA-seq analysis ($n = 4$) (Supplementary Table 8). **e**, Relative mRNA levels of genes under GO:BP analysis term ‘Cholesterol metabolism’ enriched in CLPP-KO cells and WT cells treated with D-2HG, obtained from RNA-seq analysis ($n = 4$) (Supplementary Table 8). **f**, Cholesterol levels in untreated WT cells, CLPP-KO mBA cells or WT cells treated with either D-2HG or simvastatin (Sim) ($n = 5$). **b–f**, Data are presented as mean $\pm$ s.d. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$, as determined by one-way ANOVA with multiple comparisons.

nuclear stiffness in CLPP-deficient cells (Fig. 7f). By contrast, ISRIB treatment did not significantly change D-2HG levels and had no effect on nuclear envelope stiffness (Extended Data Fig. 6e). These findings establish a functional link between altered metabolism and nuclear morphology, regulated by D-2HG, but independent of the classical ISR.

Cholesterol increases membrane stiffness, especially in saturated lipid environments, with a weaker effect in unsaturated lipid-rich membranes⁴⁷. Although the nuclear envelope is mainly composed of unsaturated phospholipids, increased cholesterol synthesis has been linked to nuclear envelope stiffening and fragility⁴⁸. Because CLPP-deficient and D-2HG-treated cells showed reduced cholesterol levels, we tested whether supplementation could restore nuclear stiffness. Cholesterol treatment significantly increased nuclear stiffness in both models, exceeding levels observed in wild-type cells (Fig. 7g). Conversely, treatment with simvastatin, a cholesterol-synthesis inhibitor, further decreased nuclear stiffness (Fig. 7g), highlighting cholesterol as a critical regulator of nuclear envelope mechanics.

To test whether these effects extend beyond CLPP deficiency, we treated wild-type mBA cells with actinonin, an inhibitor of OXPHOS biogenesis⁴⁹. Short-term actinonin treatment significantly increased 2HG levels in wild-type mBA cells and modestly elevated lipid accumulation

(Fig. 7h,i), suggesting that metabolic reprogramming occurs rapidly upon mitochondrial dysfunction. This was accompanied by a more than twofold reduction in nuclear stiffness (Fig. 7j), suggesting that OXPHOS impairment broadly influences nuclear mechanics through rapid metabolic rewiring.

Collectively, our findings reveal that mitochondrial dysfunction drives metabolic reprogramming that reshapes nuclear architecture and mechanics. We propose that PHGDH activation and subsequent D-2HG accumulation induce nuclear softening, which is reversible and cholesterol-sensitive (Fig. 7k). Although our study centres on BAT whitening and CLPP loss, similar metabolic–nuclear coupling is likely to occur in other contexts of OXPHOS dysfunction and lipid accumulation, warranting further investigation.

Discussion

This study identifies a mechanism by which CLPP loss and resulting OXPHOS dysfunction drive LD expansion, a key feature of BAT whitening, through metabolic and epigenetic adaptation. LD enlargement and BAT whitening are observed in various models of mitochondrial dysfunction and are often linked to respiratory-chain deficiencies^{22–24}. Although impaired fatty acid oxidation (FAO) is frequently proposed




Fig. 7 | 2HG mediates nuclear softening in CLPP-deficient adipocytes.

a, Representative TEM image from BAT of WT and CLPP-KO mice. LDs (yellow), nucleus (blue) and mitochondria (red) ($n = 3$ mice). Scale bars, 2 μm . **b**, 3D reconstruction of serial TEM images from KO BAT tissue (Supplementary Video 1). Scale bars, 1 μm . **c**, Quantification of nuclear dents in mitochondria ($n = 176$ fields for WT and $n = 150$ for KO, from two mice per group). **d–g**, Quantification of Young's modulus from AFM-mediated force spectroscopy of mBA nuclei from: WT and CLPP-KO ($n = 269$ for WT and $n = 260$ for KO, each from four individual cell culture plates) (**d**); untreated WT or D-2HG-treated WT (WT + HG) ($n = 772$ for WT $n = 642$ for WT + HG, each from four cell culture plates) (**e**); CLPP-KO, either untreated (KO) or treated with NCT503 (KO + NCT) ($n = 1,006$ for KO, $n = 735$ for KO + NCT, each from four cell culture plates) (**f**); WT, CLPP-KO and WT treated with D-2HG, supplemented with cholesterol (Ch) (**g**). Untreated WT simvastatin (Sim)-treated cells were used as controls ($n = 80$ for WT, $n = 169$ for

WT + HG, $n = 143$ for WT + HG+chl $n = 151$ for sim, $n = 177$ for KO and $n = 171$ for KO+chl, from three cell culture plates). **h**, 2HG levels as determined by targeted metabolomics in WT and actinonin-treated (WT + Act) mBA cells ($n = 5$). **i**, Lipid levels in WT, actinonin-treated WT cells and CLPP-KO mBAs, normalized to the average MFI value of WT cells ($n = 11$). **j**, Quantification of Young's modulus of nucleus of WT mBAs, CLPP-KO and WT cells treated with actinonin (WT + Act) ($n = 107$ for WT, $n = 158$ for WT + Act and $n = 115$ for KO, from three cell culture plates). **k**, Schematic summarizing the major findings of the study. **c, h, i**, Data are presented as mean $\pm$ s.d. **d–g, j**, Data are presented using Tukey's box plot with middle line marking the median, and whiskers show variability within 1.5 $\times$ IQR. Anything beyond is an outlier presented as individual value. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$, as determined by unpaired two-tailed Student's t -test in **c, h** and **i** and Kolmogorov–Smirnov test in **d–g** and **j**. The schematic in **k** was created using Biorender.com.

as a cause, direct mechanistic evidence is limited, as seen in models like adipocyte-specific TFAM deletion²⁴. Other studies, such as the one conducted on *Mfn2*-deficient adipocytes, suggest that reduced lipolysis, rather than increased lipogenesis, underlies LD accumulation²³. However, not all OXPHOS deficiencies result in larger LDs. For instance, mtDNA mutator mice exhibit BAT dysfunction without LD expansion, likely due to systemic metabolic constraints and a catabolic state that limits lipid storage⁵⁰.

Interestingly, BAT-specific OPA1 loss leads to LD accumulation and reduced oxygen consumption but paradoxically enhances thermogenesis through FGF21 induction²². Conversely, OPA1 overexpression protects against diet-induced obesity by preventing BAT whitening and stimulating WAT browning, potentially through fumarate-driven activation of KDM3A⁵¹. These findings underscore the complexity of mitochondrial stress responses and their influence on adipocyte fate through metabolic–epigenetic cross-talk.

Our data suggest that LD expansion and BAT whitening in CLPP-deficient models are a stress response to mitochondrial dysfunction, rather than a direct consequence of respiratory failure. This phenotype was consistent across *in vivo* models and terminally differentiated CLPP-KO brown adipocytes. Although LDs are typically considered energy reservoirs, they also serve protective roles, buffering oxidative stress, mitigating endoplasmic-reticulum stress and sequestering harmful lipid species⁵². LD expansion can limit polyunsaturated fatty acid oxidation and reduce lipotoxicity, which is particularly important under mitochondrial dysfunction, during which acylcarnitines, ceramides and oxidized lipids can accumulate⁵³. Thus, we propose that LD biogenesis acts as an adaptive mechanism to maintain redox balance and prevent metabolic toxicity^{52,53}.

We further show that LD expansion is driven by increased D-2HG levels, produced through promiscuous activity of PHGDH⁴⁰ in CLPP-deficient adipocytes. Exogenous D-2HG recapitulates the phenotype in wild-type cells, and transcriptomic analysis reveals shared signatures affecting lipid and cholesterol metabolism. PHGDH, a key enzyme in serine biosynthesis and one-carbon metabolism, is frequently upregulated in mitochondrial disease models^{5–7,54}. Given its central role in the mitoISR, inhibiting PHGDH in mitochondrial disease models, such as Deletor mice, is detrimental⁵⁴. Our findings suggest that PHGDH-derived D-2HG has an additional role in modulating lipid metabolism and chromatin architecture.

Although D-2HG is best known for its role in cancer, it also functions in hypoxia, immune-cell differentiation and metabolic disorders⁵⁵. In tumours, it inhibits α -KG-dependent dioxygenases, such as TET2 and Jumonji-C demethylases, thereby altering DNA and histone methylation⁵⁵. These changes can shift cell fate and are associated with increased repressive marks, such as H3K9me3 and H3K27me3, without widespread changes in DNA methylation⁵⁶. D-2HG also exerts non-cell-autonomous effects; for example, tumour-derived D-2HG suppresses CD8⁺ T cell metabolism and function⁵⁷. In accordance with this, we observed 2HG secretion from mature brown adipocytes, raising the possibility of systemic effects in CLPP-deficient animals.

Our findings reveal new functions for D-2HG, demonstrating its role in regulating nuclear mechanics in terminally differentiated cells. Both CLPP deficiency and D-2HG treatment led to nuclear softening, associated with increased H3K4me3 occupancy at promoter regions. This included lipid metabolic regulators involved in lipogenesis, lipolysis and transport, consistent with LD expansion. Notably, although H3K4me3 was enriched at the promoters of cholesterol-biosynthesis genes, their expression and total cholesterol levels were reduced. This indicates that there are additional regulatory layers influenced by D-2HG.

Cholesterol is essential for membrane rigidity, including at the nuclear envelope. We show that cholesterol depletion causes nuclear envelope softening, whereas supplementation restores nuclear stiffness in CLPP-deficient and D-2HG-treated cells. This aligns with prior work showing that staurosporine-induced mitochondrial dysfunction

alters mitochondria–nucleus interactions and cholesterol distribution⁵⁸. Similarly, in yeast, oxygen deprivation enhances the impact of saturated lipids, leading to nuclear envelope rigidification and rupture, while revealing a protective role for LDs in buffering membrane composition and preserving nuclear envelope integrity⁵⁹. Our data suggest that, in brown adipocytes, LD expansion might serve a similar protective role for the nuclear envelope.

Recent studies have shown that, under mechanical confinement, mitochondria migrate toward the nucleus, resulting in increased nuclear ATP to support chromatin reorganization and DNA repair⁶⁰. Nuclear stiffness depends on both the nuclear lamina and heterochromatin, which provides structural support and mechanical resistance⁶¹. Cells sense deformation through nuclear envelope stretching, which triggers membrane phospholipid restructuring and actomyosin cytoskeleton changes⁶¹. Loss of heterochromatin has been linked to nuclear envelope softening and nuclear wrinkling^{61,62}. In CLPP-deficient models and upon D-2HG treatment, we consistently observed changes in transcripts and proteins related to actomyosin cytoskeletal organization and cell adhesion and migration, consistent with responses seen under mechanical confinement^{60,62}.

In conclusion, our study links mitochondrial dysfunction to nuclear reshaping, showing how CLPP loss and D-2HG-driven metabolic rewiring affect gene expression and nuclear structure to promote lipid-droplet accumulation. We identified D-2HG as a key mediator in this process, accumulating in CLPP-deficient BAT owing to increased PHGDH activity. This metabolite reshapes the epigenetic landscape by enriching H3K4me3 histone marks on promoters of lipid-metabolism regulators, orchestrating a shift toward LD accumulation, likely as a protective sink for potentially lipotoxic intermediates. Additionally, our findings highlight an unexpected interplay between cholesterol metabolism, cytoskeletal organization and nuclear mechanics, showing that changes in cholesterol availability contribute to nuclear softening. Although our focus is on brown adipocytes, these findings could extend broadly to tissues undergoing mitochondrial stress, with relevance to ageing, metabolic disease and cancer. By connecting mitochondrial dysfunction, chromatin reorganization, lipid metabolism and nuclear mechanics, our study provides a framework for understanding adaptive tissue remodelling in mitochondrial disorders.

Methods

Animal care and breeding

All mice analysed in this study were bred and housed at the CECAD Research Center animal facility, University of Cologne. All experiments were conducted in compliance with National Institutes of Health guidelines and approved by local government authorities (Landesamt für Natur, Umwelt und Verbraucherschutz Nordrhein-Westfalen; LANUV). Mice were housed in individually ventilated cages at 22–24 °C under a 12-h light–dark cycle, with lights on at 06:00. They had *ad libitum* access to water and a standard chow diet (ssniff rat/mouse low-phytoestrogen diet). For breeding, one male was paired with one to two females of similar age, with mating initiated at a minimum age of 8 weeks. Body weight was recorded weekly for individual mice from 4 to 16 weeks of age.

The mice used in this study were derived from a line with a conditional *Clpp* gene targeting, as previously described²⁹. To generate whole-body CLPP-KO mice (*Clpp*^{−/−}), *Clpp*^{fl/fl} mice were crossed with transgenic mice ubiquitously expressing Cre recombinase under the control of the β -actin promoter. Mice with adipose-tissue-specific knockout were generated by crossing *Clpp*^{fl/fl} mice with transgenic mice expressing Cre recombinase under the control of the *Adipoq* promoter (*Adipoq-cre* mice)³⁰ or the *Ucp1* promoter (*Ucp1-cre* mice)³¹.

In vivo NCT injections in mice

Each day for 15 days, 14-month-old male mice were intraperitoneally injected daily with vehicle (ethanol (5%), PEG400 (35%) and 30%

cyclodextrin (60%)), in which NCT503 was dissolved. NCT-503 was freshly prepared prior to the injections. For the injection solution, 20 μ M stock was dissolved in the vehicle and was administered to the mice at serum-stable concentrations of 40 mg kg⁻¹ body weight⁴².

Tissue histology and haematoxylin and eosin staining

After dissection, the entire adipose tissues were placed in tissue cassettes (Roth) and fixed in 5% (wt/vol) paraformaldehyde overnight at 4 °C. Tissues were then stored in PBS until they sank to the bottom. The next day, they were dehydrated in increasing ethanol concentrations (30%, 50%, 70%, 96% and twice in 100%) for 2 h at each step, followed by two 2-h incubations in xylol. Finally, tissues were embedded in paraffin blocks. The fixed BAT and inguinal WAT (iWAT) were sectioned at 5- μ m thickness using a microtome (Leica) and mounted on poly-L-lysine-coated glass slides (VWR). Paraffin-embedded BAT sections were deparaffinized in xylol and rehydrated through decreasing ethanol concentrations, followed by a wash in tap water. Sections were stained with Meyer's haematoxylin, rinsed and then counterstained with eosin. Sections were then dehydrated in increasing ethanol concentrations, cleared in xylol and mounted with entellan.

Electron microscopy and 3D reconstruction of adipose tissue

Sample preparation and embedding. Adipose tissue samples were immersion-fixed in 2% formaldehyde and 2% glutaraldehyde in 0.1 M sodium cacodylate buffer (Applichem) and washed four times in the same buffer. Post-fixation was performed with 2% OsO₄ (Science Services) in 0.1 M cacodylate buffer at 4 °C, followed by additional washes. Samples were dehydrated in an ascending ethanol series (50%, 70%, 90%, 3×100%), treated with ethanol and propylene oxide and infiltrated with epon and propylene oxide at gradually increasing concentrations of epon. Samples were embedded in PELCO 21-cavity molds (Plano) and cured at 60 °C.

Ultrathin sectioning and transmission electron microscopy.

Ultrathin sections (70 nm) were cut using an ultramicrotome (Leica UC6) with a 45° diamond knife (Diatome). Sections were stained with uranyl acetate and lead citrate and imaged using a JEM-2100 Plus TEM (JEOL) operating at 80 kV, equipped with a OneView 4 K camera (Gatan).

Serial sectioning and 3D reconstruction. Ribbons of five consecutive ultrathin sections were collected on Pioloform-coated slot grids (Science Services). A total of 60 sections were imaged for 3D reconstruction. Images were aligned using Fiji (TrakEM2 plugin), and nucleus, mitochondria and lipid droplets were manually segmented in Microscope Imaging Browser (MIB, v2.82). The final model was processed in IMARIS (v9.9.1) for 3D reconstruction.

Quantification of mitochondrial density

Transmission electron micrographs (TEMs) at ×2,500 magnification were used to quantify mitochondria in wild-type and knockout conditions. Forty-eight images per condition were captured from random sample positions. Mitochondrial quantification was performed using unbiased counting frames in ImageJ (Fiji). For each image, a 3×3 grid of counting frames covering 25% of the image was randomly placed. Mitochondria fully enclosed or intersecting permissive lines were counted; those intersecting restrictive lines were excluded. The multi-point tool in Fiji was used for tracking. The numerical density (*N*) of mitochondria was calculated as: $N = (\text{number of mitochondria} / \text{number of counting frames}) \times \text{area per frame} (\mu\text{m}^2)$.

Quantification of lipid droplet density and area

Low-magnification TEM micrographs (×80–150 magnification) were acquired, including 20 images from knockout and 12 from wild-type samples. The largest possible rectangular sample regions were extracted using Fiji, excluding grid and void areas. For 12 images per

condition, 512×512 pixel regions were cropped and segmented using the Cellpose cyto3 model. Segmentation results were saved as ImageJ ROI files, manually corrected in QuPath and re-applied to all extracted regions using a refined Cellpose model. Lipid-droplet number and size were measured using a Fiji macro. A guard zone (15% of image diameter) was applied to exclude lipid droplets cut off by image borders. To avoid biased exclusion, the lower and left boundaries were restrictive (excluding intersecting droplets), while the upper and right boundaries were permissive (including intersecting droplets).

Primary brown adipose tissue mesenchymal stem cells cultures and their differentiation to mature brown adipocytes

Isolation of brown adipose tissue mesenchymal stem cells cultures.

A six-well plate was prepared with BAT collagenase digestion buffer (123 mM NaCl, 5 mM KCl, 1.3 mM CaCl₂, 5 mM glucose and 100 mM HEPES, pH 7.4) on ice. Sterile equipment (Falcon tubes, reaction tubes, syringes, cannulas and a dish) was disinfected with 70% ethanol. The two brown fat pads were dissected from newborn mice, placed in collagenase digestion buffer, minced with scissors and transferred to a Falcon tube on ice. A tail tip was collected in a reaction tube for genotyping. For collagenase digestion, Falcon tubes were incubated in a water bath with gentle shaking until complete tissue dissociation. The suspension was drawn into syringes using 0.9 × 70 mm (20 G × 2) cannulas, then filtered through a 100- μ m nylon mesh into a fresh Falcon tube. The middle phase was carefully collected, avoiding the upper (mature adipocytes) and lower (tissue remnants) phases. The suspension was then filtered through a 30- μ m nylon mesh and centrifuged. The cell pellet was resuspended in brown adipose tissue mesenchymal stem cell culture medium and transferred to a six-well plate for further analyses.

Immortalization of brown adipose tissue mesenchymal stem cells.

Primary brown adipose tissue mesenchymal stem cells (passage 0) were immortalized 24 h post-isolation through lentiviral transduction with a virus expressing SV40 large T-Antigen (L-Tag) under the PGK promoter. Immortalized brown preADs (mBA) were expanded in mBA growth medium at 37 °C, 5% CO₂. The virus solution was thawed and centrifuged at 16,000g, and 200 ng viral reverse transcriptase (per well of a 6-well plate) was mixed with 800 μ l brown adipocyte (BA) growth medium (high-glucose DMEM without pyruvate). After removing the culture medium, cells were exposed to viral medium, followed by PBS washes and replacement with fresh BA growth medium.

Cultivation and storage of brown adipose cells. Cells were maintained in growth medium at 37 °C, 5% CO₂, ensuring cultures did not reach full confluence. For passaging, cells were detached through trypsinization, resuspended in growth medium, and centrifuged at 200g. Pellets were resuspended in growth medium and mixed 1:1 with freezing medium to achieve a final DMSO concentration of 10% at a cell density of 1 million cells ml⁻¹. Cell suspensions were transferred to cryogenic vials (1 ml per vial) and stored at -80 °C, followed by transfer to liquid nitrogen (-196 °C) for long-term storage.

Differentiation of mature brown adipocytes. In each well of a six-well plate, 1.8 × 10⁵ cells were seeded in growth medium (day -4). Once confluent, the medium was replaced with differentiation medium (growth medium + 0.5 μ g ml⁻¹ insulin + 1 nM triiodothyronine) (day -2). Adipogenic differentiation was induced by switching to freshly prepared induction medium (growth medium + 5 μ M dexamethasone + 250 μ M IBMX (3-Isobutyl-1-methylxanthine) + 0.5 μ g ml⁻¹ insulin + 1 nM triiodothyronine (day 0). After induction, cells were maintained in BA differentiation medium, which was replenished every second day. By day 8, cells were fully differentiated into mature brown adipocytes.

Cell culture treatments

Treatments were initiated from day 3 upon switching to differentiation medium: actinonin (150 μ M, DMSO; applied for 96 h, with replacement every second day); NCT-503 (20 μ M, DMSO; applied for 72 h, with replacement every 24 h); octyl D-2HG (500 μ M, DMSO; applied for 72 h, with replacement every 24 h); and ISRIB (1 μ M, DMSO; applied for 72 h, with daily renewal).

Lipid content analysis

BODIPY staining and FACS. Cells were washed with PBS and stained with 1 $\times$ BODIPY solution in PBS in the dark. After staining, cells were trypsinized, and trypsinization was stopped with FACS buffer (PBS + 2% BSA). The cell suspension was filtered through a 60- μ m strainer and transferred to fresh Eppendorf tubes for analysis. The gating strategy used for flow cytometry analysis is provided in Supplementary Figure 1a.

Oil red O staining. Cells were washed with PBS and fixed in 10% formalin for 30 min at room temperature. After fixation, cells were washed twice with water, followed by a 5-min wash with 60% isopropanol at room temperature. The cells were then completely dried. A working solution of Oil red O (ORO) was added to the wells and incubated for 10 min at room temperature. After incubation, cells were washed four times with water, and images were acquired for further analysis. The ORO stock solution was prepared as 0.35% ORO in isopropanol, and the working solution was prepared with 60% of ORO stock in water.

Immunofluorescence staining

Cells were seeded and differentiated on coverslips before direct fixation with 4% paraformaldehyde in PBS (pH 7.4) at room temperature, followed by washes with PBS. Blocking was performed with 5% BSA and 0.3% Triton X-100 in PBS. Coverslips were incubated with primary antibodies diluted in 1% BSA and 0.3% Triton X-100 in PBS at 4 $^{\circ}$ C, followed by PBS washes. Secondary antibodies were applied in 0.3% Triton X-100 in PBS in the dark, followed by final PBS washes. Coverslips were dipped in water, mounted on elvanol and imaged using an SP8 confocal microscope (Inverse, DMi 8 CS, Leica Microsystems).

Ex vivo adipocyte lipolysis assay

To assess lipolytic activity in BAT from CLPP-KO and control mice, mice were fasted for 6 h, and BAT pads were excised under sterile conditions. Tissues were digested with collagenase type 2 (Worthington Biomedical) in Krebs-Ringer Solution (KRH) + 1% BSA. For each condition, BAT adipocytes from 4–5 mice were pooled, and 150,000–200,000 isolated adipocytes were incubated in KRH buffer + 4% BSA with either 15 nM isoproterenol (ISO) or 10 μ M forskolin. Lipolysis was assessed by measuring free glycerol release in the supernatant using Free Glycerol Reagent (Sigma-Aldrich), with absorbance recorded on a Synergy H1 plate reader (BioTEK). Glycerol content was normalized to total protein content, determined by the Pierce Bradford Assay Kit (Thermo Scientific).

Ex vivo oxygen consumption rate in BAT lysates

Oxygen consumption in BAT tissue lysates was measured using an OROBROS Oxygraph-2K electrode at 37 $^{\circ}$ C with magnetic stirring. Samples were placed in 2 ml incubation medium (containing EGTA, $MgCl_2$, K-lactobionate, taurine, KH_2PO_4 , HEPES, sucrose and BSA; pH 7.1). In vitro respiration levels were recorded at steady state, followed by sequential addition of the following substrates: endogenous (state 1), ADP (state 2), succinate (state 3), oligomycin (state 4) and FCCP (uncoupled respiration). Respiration rates were normalized to total protein content.

Respiration analysis using Seahorse XFe-96 Analyzer

Mitochondrial OCR and ECAR were measured using the Seahorse Bioscience XFe-96 Analyzer (Agilent Technologies) following the standard

mitochondrial stress test protocol. Differentiated mBA cells (day 8) were assayed. Cells were washed with unbuffered assay medium (DMEM without phenol red, supplemented with glucose, sodium pyruvate and glutamine) and incubated in a CO_2 -free incubator at 37 $^{\circ}$ C. The sensor cartridge was hydrated and injection ports were loaded with oligomycin (1 μ M), FCCP (1.5 μ M) and rotenone-antimycin A (1 μ M each) before calibration. The assay was then performed, and post-measurement normalization was conducted using BioTek Cytation 5 (Agilent Technologies) with Hoechst 33342 staining for cell counting. Data analysis was performed using Seahorse XFe Wave Software (Agilent). Basal respiration, leak respiration, maximal respiration and acidification were calculated on the basis of OCR and ECAR values before and after specific injections, with non-mitochondrial oxygen consumption corrected using rotenone and antimycin A.

Atomic force microscopy measurements on cultured cell nuclei

AFM measurements were performed on cell monolayers plated on silicon elastomers using the JPK NanoWizard 4 XP (Bruker Nano) atomic force microscope mounted on Zeiss AxioObserver inverted fluorescent microscope and operated through JPK SPM Control Software v.5. Triangular non-conductive silicon nitride cantilevers (MLCT, Bruker Daltonics) with a nominal spring constant of 0.01 N m^{-1} were used for the nanoindentation experiments of the apical surface of cells and the nucleus. For all indentation experiments, forces of up to 3 nN were applied, and the velocities of the cantilever approach and retraction were kept constant at 2 μ m s^{-1} , ensuring an indentation depth of 500 nm. All analyses were performed with JPK Data Processing Software (Bruker Nano). Before fitting the Hertz model corrected by the tip geometry to obtain Young's modulus (Poisson's ratio of 0.5), the offset was removed from the baseline, the contact point was identified, and cantilever bending was subtracted from all force curves.

Lentivirus production and stable cell line generation

To overexpress D-2HGDH in wild-type and CLPP-KO mBA cells, a lentiviral transfer plasmid encoding D-2HGDH-hemagglutinin (HA) (VectorBuilder) was used. Lentivirus was produced in HEK293FT cells via cotransfection of the D-2HGDH-HA plasmid with psPAX2 (Addgene plasmid no. 12260) and pMD2.G (Addgene plasmid no. 12259) using Lipofectamine 2000 (Invitrogen). Viral supernatants were collected, pooled, clarified by centrifugation and concentrated with Lenti-X Concentrator (Takara Bio). The viral pellet was resuspended in PBS, aliquoted and stored at -80° C.

Transduction of mBA cells. Wild-type and CLPP-KO mBA cells were seeded in 6-well plates and transduced with 10 μ l concentrated lentivirus in 6 μ g ml^{-1} polybrene. After 24 h, the medium was replaced, and cells were expanded before puromycin selection (2 μ g ml^{-1} , 48 h).

PHGDH activity assay

The PHGDH activity assay was performed using the ab273328 kit (Abcam), following the manufacturer's instructions. In brief, cells in a 6-well plate were washed with PBS, homogenized on-plate in PHGDH Assay Buffer and centrifuged at 10,000g, 4 $^{\circ}$ C. The supernatant was collected, and total protein concentration was determined using a BCA assay. Then, 30 μ g of protein was loaded into a 96-well plate, with the final volume adjusted to 50 μ l using PHGDH assay buffer. A NADH standard curve was generated using dilutions of 1.25 mM NADH standard, and a PHGDH positive control was prepared. A reaction mix of assay buffer and developer was added to all wells. Absorbance at 450 nm was measured in kinetic mode at 37 $^{\circ}$ C using an EnSpire plate reader.

RNA isolation from mouse tissues and primary adipocytes

Total RNA was isolated from mouse BAT and primary adipocytes using TRIzol (Life Technologies) or TRI reagent (Sigma), followed by purification with RPE buffer (Qiagen). Tissues were homogenized in 1 ml TRIzol

using ceramic beads (Mobio, Dianova) in a FastPrep homogenizer (MP Biomedicals) at 5,500 r.p.m. After incubation at room temperature, 200 μ l chloroform was added, mixed and centrifuged at 12,000g, 4 $^{\circ}$ C. The aqueous RNA-containing phase was collected and precipitated with 500 μ l isopropanol, followed by washing with 75% ethanol and resuspension in ultrapure H₂O. RNA was incubated at 60 $^{\circ}$ C before a concentration and purity assessment using a NanoDrop ND-1000 UV-Vis spectrophotometer (Peqlab). For DNase treatment, 10 μ g RNA was digested with DNase I (New England Biolabs) in 10 $\times$ digestion buffer. DNase was inactivated at 75 $^{\circ}$ C, and the RNA concentration was reassessed before storage at -80° C. The RNA quality was validated using the Agilent RNA 6000 Nano Kit on an Agilent 2100 Bioanalyzer (Agilent Technologies).

Quantitative PCR

Isolated RNA was treated with DNase I (New England Biolabs) to digest the residual DNA, following the manufacturer's protocol. The concentration of the samples was adjusted to 200 ng μ l⁻¹. Next, complementary DNA (cDNA) was synthesized from the digested samples using the High-Capacity Reverse Transcription kit (Applied Biosystems). Quantitative PCR (qPCR) reactions were performed in 384-well plates using the Brilliant III Ultra-Fast SYBR Green qPCR Master Mix (Agilent Technologies), according to the manufacturer's instructions; 50 ng of cDNA was added to each reaction. The standard programme was run at the Applied Biosystems QuantStudio 7 Flex Real-Time PCR System (Fisher Scientific). The qPCR data were collected using the QuantStudio 12 K Flex Software v1.6 (Applied Biosystems). Relative expression of the target gene was calculated by normalization to endogenous control gene (*Hprt*) and was quantified using the 2^{- $\Delta\Delta C_t$} method.

Isolation of cytoplasmic and peri-lipid-droplet mitochondria from BAT

BAT was collected, rinsed in PBS, weighed and minced with fine scissors. The minced tissue was suspended in SHE-BSA buffer (50 mM sucrose, 5 mM HEPES, 2 mM EGTA, pH 7.2, 2% FFA BSA) at 1 ml per 100 mg tissue. Homogenization was performed using a glass-Teflon electric homogenizer (7 strokes) followed by a glass-glass Dounce homogenizer (13 strokes). The homogenate was transferred to a 50-ml Falcon tube, and residual tissue was washed out with SHE-BSA buffer. Centrifugation at 900g (4 $^{\circ}$ C) separated the fractions. The supernatant, containing cytoplasmic mitochondria, was carefully collected using a syringe, avoiding disruption of the floating fat layer or debris pellet. The fat layer, containing lipid-associated PDMs, was scraped into a new tube, resuspended in SHE-BSA buffer, and vigorously shaken to emulsify the fat and release PDMs. Both fractions (cytoplasmic mitochondria and PDMs) were centrifuged at 9,000g (4 $^{\circ}$ C), and pellets were washed in SHE-BSA buffer, transferred to 1.5-ml Eppendorf tubes and centrifuged again. The final pellets were resuspended in SHE buffer without BSA for immediate analysis or snap-frozen in liquid nitrogen for long-term storage. BAT was collected and rinsed twice in PBS.

Protein isolation

Tissue lysis. BAT pads were homogenized in 700–800 μ l cold organ lysis buffer (50 mM HEPES pH 7.4, 50 mM NaCl, 1% Triton X-100, 100 mM NaF, 10 mM EDTA, 0.1% SDS, 10 mM Na-orthovanadate, 2 mM PMSF, 1 $\times$ protease inhibitor cocktail (Sigma-Aldrich), 1 $\times$ PhosphoSTOP phosphatase inhibitor cocktail (Roche)) using 1.4 mm ceramic beads (Omni International) in a Precellys tissue homogenizer (Bertin Technologies) at 5,500 r.p.m. (2 $\times$ 20 s, 30 s pause). Lysates were cleared by centrifugation (20,000g, 4 $^{\circ}$ C, 45 min) and transferred to fresh tubes.

Cell lysis. Cells were washed with PBS and lysed on-plate using RIPA buffer (50 mM Tris-HCl pH 7.4, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 150 mM NaCl, 2 mM EDTA, 50 mM NaF, 1 $\times$ protease inhibitor cocktail). Lysates were incubated on ice for 30 min

with occasional vortexing, followed by 10 cycles of sonication (30-s intervals, 4 $^{\circ}$ C) using the Bioruptor Pico (Diagenode). Cell debris was pelleted (14,000g, 4 $^{\circ}$ C, 15 min), and the supernatant was collected.

In both cases, the protein concentration was measured using the Bradford assay (Sigma-Aldrich), following the manufacturer's instructions. Lysates were stored at -80° C.

SDS–polyacrylamide gel electrophoresis and western blot

Proteins were separated by SDS–polyacrylamide gel electrophoresis (SDS–PAGE) using the Mini-PROTEAN Tetra Cell (BioRad). Fifty micrograms of protein lysate was mixed with Laemmli buffer (50 mM Tris-HCl, 2% SDS, 10% glycerol, 1% 2-mercaptoethanol, 12.5 mM EDTA, 0.02% bromophenol blue, pH 6.8) and incubated at 95 $^{\circ}$ C for 5 min. Samples were loaded onto an 8–12% polyacrylamide gel alongside a PageRuler Prestained Protein Ladder (Thermo Fisher Scientific). Electrophoresis was performed at 90 V until the loading dye reached the separating gel, followed by 150 V until completion in running buffer (25 mM Tris-HCl, 250 mM glycine, 0.1% SDS, pH 8.3).

Proteins were transferred to a nitrocellulose membrane using the Criterion Blotter (BioRad) through wet transfer at 400 mA in transfer buffer (30 mM Tris-HCl, 240 mM glycine, 0.037% SDS, 20% methanol) at 4 $^{\circ}$ C. Transfer efficiency was assessed with Ponceau-S staining (Sigma-Aldrich). Membranes were blocked in 5% milk-PBST, 3% BSA-TBST or 2% fish skin gelatin-TBST, depending on antibody requirements.

Membranes were incubated overnight at 4 $^{\circ}$ C with primary antibodies, followed by three 5-min washes in PBST or TBST. Secondary antibody incubation was performed at room temperature, followed by additional washes. Detection was performed using ECL solution (GE Healthcare), and membranes were exposed to Super RX films (Fujifilm), developed using an automatic film processor (Kodak) and scanned with a V800 Transparency Scanner (Epson) at 600 dpi, 16-bit grayscale.

Blue native polyacrylamide electrophoresis

Blue native (BN)–PAGE was performed using the NativePAGE Novex Bis-Tris Gel System (Life Technologies), according to the manufacturer's instructions. Ten micrograms of mitochondria were lysed in 4% digitonin, and lysates were cleared by centrifugation (20,000g, 4 $^{\circ}$ C). Supernatants were mixed with loading dye (50% glycerol, 5% Coomassie) and loaded onto 4–16% native acrylamide gels (Life Technologies). Electrophoresis was conducted at 4 $^{\circ}$ C, 150 mV. Antibodies used for BN–PAGE were as follows: ATP5A1 (Abcam ab14748) 1:1,000; NDUFA9 (Molecular Probes 459100) 1:1,000; NDUFV1 (Proteintech 11238-1-AP) 1:1,000; SDHA (Molecular Probes 459200) 1:10,000; UQCRC1 (Molecular Probe 459140) 1:1,000.

In-gel activity assay for complex I and V

After BN–PAGE, the gel was washed and incubated in NADH-nitroreductase solution (0.1 mg ml⁻¹ NADH, 2.5 mg ml⁻¹ nitroreductase, 5 mM Tris-HCl, pH 7.4) at 37 $^{\circ}$ C for complex I activity. Gels were then destained in 50% methanol, 10% acetic acid and rehydrated in double-distilled H₂O. For complex V activity, the gel was incubated in assay buffer (35 mM Tris-HCl, 270 mM glycine, 14 mM magnesium sulfate, 0.075% lead nitrate, 0.8 mM ATP, pH 7.8, 20% methanol). ATP hydrolysis was visualized as a white band of precipitated lead phosphate. The reaction was stopped with 50% methanol, and the gel was rinsed with deionized water. The gel was documented using a V800 Transparency Scanner (Epson).

Proteomics: label-free quantification of tissue proteomes

The entire piece of frozen adipose tissue was ground to powder in liquid nitrogen and after the liquid nitrogen evaporated, the powder was resuspended in 100 μ l of the urea lysis buffer (8 M urea; 50 mM triethylammonium bicarbonate (TEAB); 1 $\times$ protease inhibitor). The sample solution was subjected to sonication with the Bioruptor Pico

sonication machine (Diagenode) with a cycle of 30 s on and 30 s off for 10 min. Afterwards, the sample was centrifuged at 20,000g for 15 min at 4 °C to pellet the debris, which was discarded after centrifugation. The protein concentration of the samples was determined using the Bradford reagent (Sigma-Aldrich), according to the manual, and 55 µg of each sample was transferred to a new tube. The sample was treated with dithiothreitol (DTT, final concentration 5 mM) and incubated at 25 °C for 1 h. Then, chloroacetamide was added final concentration 40 mM) and incubated for 30 min in the dark. This was followed by treatment with lysyl endopeptidase (Lys-C), a protease to sample protein ratio of 1/75 and then incubated for 4 h at 25 °C. The sample was next diluted with 50 mM TEAB buffer to reach a final concentration of ≤ 2 M urea. Then, trypsin was added at a 1:75 ratio, and trypsinisation was performed overnight at 25 °C with mild agitation. The following day, the sample was acidified with formic acid (final concentration 1%) to stop the digestion. Next, lysates were loaded on SDB RP StageTips supplied by the CECAD proteomics core facility and submitted to the facility for mass spectrometry (MS) analysis, following the standard procedures of the facility. The raw data were analysed with the MaxQuant proteomics software. The samples were analysed by CECAD proteomics facility.

mRNA sequencing and differential expression analysis

mRNA sequencing was performed in-house using 1 µg total RNA for library preparation with the NEBNext RNA Prep Kit, followed by paired-end (2×50 bp) sequencing on an Illumina NovaSeq 6000. Sequencing reads were aligned to the mouse reference genome (Gencode vM25) using STAR aligner (v2.7.9a). Gene features were counted using featureCounts (v2.0.3), and genes with low expression levels were filtered out using edgeR (v4.0.16) with the filterByExpr function. For the Embryo Inject dataset, a more rigorous filtering approach was applied (with a minimum count of 40). Differential expression analysis was conducted using edgeR's voomLmFit function with sample quality weights (sample.weights = TRUE) in a linear model (0 + group), where 'group' represented the experimental conditions. Genes with an adjusted $P < 0.05$ were considered differentially expressed.

Bulk deconvolution

To assess whether genotype-specific differences in bulk gene expression were influenced by cell-type composition, the BisqueRNA R package was used to estimate cell-type proportions from bulk RNA-seq read counts. The Shamsi et al. dataset was selected as a single-cell reference owing to its similar tissue origin³⁴. Because only marker genes for UMAP clusters were available, the original UMAP projection was reconstructed and clustered using the Seurat FindClusters function (resolution, 1.4). However, later analyses suggested that a resolution of 0.4 might have been a better choice. For consistency with the original procedure, Seurat v3.0 and R v3.6.2 were used.

Cell-type assignment. Cell-type scoring was performed using UCell (v2.0.1), with the ten strongest positive and negative marker genes per cluster. Because UCell scores alone do not always provide unique assignments, two approaches were tested. The first was clustering the ucell score matrix: the ComplexHeatmap package (v2.12.1) was used to cluster cells by their UCell scores, revealing groups of related cell types. However, owing to memory constraints, clustering was performed on 200 random sub-matrices, and thresholds for defining clusters remained arbitrary. The second was identifying high-scoring cell types in UMAP clusters: a one-sided t -test compared each cell type's UCell score distribution within a cluster to its global distribution. If only one cell type showed significant enrichment, the cluster was uniquely assigned. If multiple cell types were significant, a coarse classification was applied. For bulk deconvolution, only samples collected at room temperature were used, restricted to genes present in both datasets (18,953 genes, 22,219 cells)³⁴. Cell-type assignments were

based on resolution-0.4 clustering, with a stringent inclusion threshold ($P \leq 2.225074 \times 10^{-308}$). This resulted in 15 cell types, of which B cells and VSM1 cells were not composite. After removing 738 unassigned cells, 21,481 cells remained. BisqueRNA was applied to the salmon.merged.gene_counts_length_scaled.tsv bulk dataset, using only BAT samples, analyzing one genotype at a time, and restricting genes to those also found in the single-cell dataset.

Genotype-specific cell-type proportions. To determine whether BAT genotypes differed in cell-type composition, the predicted coarse cell-type proportions were examined. However, high variability in genotype replicates made it difficult to draw statistical conclusions. Additionally, proportion data are compositional, meaning changes in one cell type's frequency inherently affect the others. Instead of statistical analysis, a visual representation was developed: Seurat UMAP coordinates were extracted. Ggplot2 was used to colour cells by their assigned coarse cell type, with predicted proportions coded by transparency in the bulk dataset. This approach revealed that resolution-0.4 clustering corresponded more clearly to high-level UMAP features than did resolution-1.4 clustering, suggesting that 0.4 might be the better choice of resolution.

ChIP-seq of H3K4me3 in mature brown adipocyte cells

ChIP-seq libraries were prepared from four biological replicates per condition (WT, KO, WT + 2HG). First, 1×10^7 cells per condition were cross-linked with 1% formaldehyde, quenched with glycine (0.125 M), washed in PBS and pelleted by centrifugation. Cells were lysed in lysis buffer (50 mM HEPES pH 7.9, 140 mM NaCl, 1 mM EDTA, 10% glycerol, 0.5% NP-40, 0.25% TritonX-100) with protease inhibitors and homogenized in a pre-chilled dounce homogenizer. Nuclei were pelleted, washed with wash buffer (10 mM Tris pH 8.0, 200 mM NaCl, 1 mM EDTA, 0.5 mM EGTA) and resuspended in shearing buffer (0.1% SDS, 1 mM EDTA, 10 mM Tris pH 8.0). Chromatin was sonicated using a Bioruptor Pico (Diagenode) for 70 cycles. For chromatin immunoprecipitation (ChIP), 30 µg of DNA was incubated with 5 µl H3K4me3 antibody (Active Motif, 39159) in 1% Triton X-100 and 150 mM NaCl. Protein G Dynabeads (Invitrogen) were prewashed with IP buffer, added to the immunoprecipitated chromatin and washed sequentially with TSE-150, TSE-500, LiCl and TE buffers. DNA was eluted in PK digestion buffer (20 mM Hepes pH 7.5, 1 mM EDTA, 0.5% SDS) with RNase A (Thermo Fisher Scientific) and proteinase K, followed by reverse cross-linking with NaCl (0.3 M). DNA purification was performed using the Nucleospin Gel and PCR Clean-up kit (Macherey-Nagel). For library preparation, up to 100 ng ChIP DNA underwent end repair, A-tailing and adapter ligation, followed by PCR amplification (12–15 cycles). Libraries were validated (TapeStation, Agilent Technologies), quantified (Qubit, Invitrogen), pooled and sequenced on an Illumina NovaSeq 6000 (paired-end 2×100 bp protocol).

Analysis of ChIP-seq data

Raw FASTQ files were processed using the SnakePipes pipeline⁶³. In brief, fastq files were trimmed with fastp using the following parameters: --trim_poly_g--trim_poly_x-Q-L--correction. Trimmed reads were mapped to the GRCm39 mouse reference genome with BWA-MEM, and peaks were called using Genrich, which integrates replicate data by computing P values per replicate and combining them using Fisher's method to generate q values for peak calling. Coverage plots and heatmaps generated using deeptools. Peak count frequency at the TSS sites and feature distribution of all identified peaks performed using ChIPseeker. Kyoto Encyclopedia of Genes and Genomes and GO analyses were conducted as described previously, focusing on differentially enriched H3K4me3 peaks within ± 2 kbp of promoter regions. Data visualization was conducted using the Integrative Genomics Viewer (<https://igv.org>) and custom plots.

GSEA analysis was performed using GSEA v4.3.2 (Windows application, build 13) with default settings⁶⁴. Data visualization was conducted using the Integrative Genomics Viewer (web-based version)⁶⁵ and custom plots.

Single-cell immunophenotyping from tissue

For single-cell suspensions, bone marrow was extracted from the femur of adult mice by flushing with 10 ml of FACS buffer using a 27-G needle and syringe, then passed through a 40-µm strainer. BAT was dissected and immediately transferred to ice-cold digestion solution. Tissues were cut in small pieces with scissors and incubated in digestion solution containing collagenase IV (1 mg ml⁻¹), and DNase I (0.01 mg ml⁻¹) in RPMI for 40 min at 37 °C in the shaker. Digestion was stopped by adding 10% FBS on ice. Tissue homogenates were smashed and washed with FACS buffer against a 70-µm strainer using the back of a syringe. Pellets were resuspended in 1 ml red blood cell lysis buffer (Roche) and incubated for 10 min at room temperature for lysis of erythrocytes.

Subsequently, 10 ml FACS buffer (5% FCS in PBS) was added and cells were centrifuged at 300g for 5 min at 4 °C. The cells were pre-incubated with fix viability dye in PBS (1:1,000) for 10 min at room temperature; for BAT, a mix of anti-mouse-FcγIII/II-receptor (CD16/CD32) blocking antibodies (1:500) was added. After being washed with FACS buffer, cells were stained with the fluorochrome-conjugated antibodies (1:100 0.25–1 µg; listed below). Only BAT cells were fixed and permeabilized using the FoxP3 kit, following the manufacturer's instructions, and were then incubated with antibodies to iNOS and Arg-1 for 20 min at room temperature for intracellular staining. After washing and filtering, cells were resuspended in 500 µl (BM) or 250 µl (BAT) FACS buffer, and 25 µl of counting beads were added to the samples (at a concentration of 1,000 beads per µl) to obtain absolute numbers. For absolute quantification, the following equation was used: absolute count (cells µl⁻¹) = (cell count × counting beads volume) / (counting bead count × sample volume) × counting bead concentration.

Each population was expressed in absolute numbers (cells µl⁻¹), and BAT results were further normalized to the initial tissue weight (g) for comparison across samples. Cells were acquired on a FACS Symphony A3 flow cytometer (BD) using Diva software (BD) and further analysed using FlowJo analytical software (FlowJo version 10.0.8). Owing to inadequate result quality, data collected for iNOS and Arg-1 were excluded from further analysis. Compensation beads were used to generate compensation panel and calculated by diva software before sample acquisition. Background fluorescence levels of iNOS, Arg-1, CD80 and CD80 were determined using Fluorescence Minus One (FMO), although data from these populations were excluded owing to low cell counts. The buffers used were as follows: FACS buffer (5 mg BSA + 5 ml EDTA 0.4 M + 500 ml of PBS); digestion buffer (250 µl DNase I (Merck, 200,000 U µl⁻¹), 0.2 mg ml⁻¹ Liberase (Roche) and 1 mg ml⁻¹ collagenase IV in RPMI medium). The details of the antibodies used can be found in the reporting summary. The gating strategy used can be visualized in Supplementary Figure 1b,c.

The antibodies used are provided in the table.

Antibody	Conjugates	Laser name in BD	Clone
CD45	FITC	BB515	30-F11
B220	Allophycocyanin (APC), Cyanine7	APC-H7	RA3-6B2
CD115	Brilliant Violet 605	VV605	AFS98
CD117	Brilliant Violet 510	BV480/510	ack2
CD11b	BUV661	BUV661	M1/70
CD11c	BUV395	BUV395	HL3
CD127 (IL-7Rα)	Peridinin-chlorophyll protein (PerCP), Cyanine5.5	BB700	A7R34

Antibody	Conjugates	Laser name in BD	Clone
CD135	Phycoerythrin (PE)	BY6584	A2F10
CD16/32	Brilliant Violet 421	BV421	93
CD172a (SIRPα)	PE, Dazzle 594	PE-CF594	P84
CD19	APC, Cyanine7	APC-H7	6D5
CD34	PE, Cyanine7	BYG790	MEC14.7
CD3E	APC, Cyanine7	APC-H7	145-2C11
CD45	Alexa Fluor 700	APC-R700	30-F11
CD49b	APC, Cyanine7	APC-H7	DX5
F4, F80	BUV395	BUV563	T45-2342
Ly-6A, Ly-6E (Sca-1)	PE, Dazzle 594	BB515	D7
MHCII	PerCP, Cyanine5.5	BB700	M5-114.15.2
NK1.1	APC, Cyanine7	APC-H7	PK136
Ter119	APC, Cyanine7	APC-H7	TER119
Ly-6A, Ly-6E (Sca-1)	PE, Dazzle 594	PE-CF594	D7
TruStain FcX (anti-mouse-CD16/CD32)	None	None	93

Metabolite extraction from tissues

Metabolite extraction solution (50% methanol, 30% acetonitrile (ACN), 20% water, 5 µM valine-d8 as an internal standard) was added to 10–20-mg frozen BAT or iWAT tissue samples at an extraction ratio of 25 µl mg⁻¹ on dry ice. Samples were then homogenized using a Precellys 24 tissue homogenizer (Bertin Technologies). The resulting sample suspension was vortexed, mixed at 4 °C in a Thermomixer for 15 min at 1,500 r.p.m. and then centrifuged at 16,000g for 20 min at 4 °C. The supernatant was collected for liquid chromatography–MS (LC–MS) analysis.

Metabolite extraction from cells

The cells were counted at seeding to estimate the amount of extraction solution to use. Using 500 µl extraction buffer per 106 cells is the recommended starting point, although the ratio might need to be optimized for certain cell types in a separate pilot experiment. The medium was removed from wells, and cells were washed quickly (less than 10 s) with PBS twice at room temperature. Extra PBS was carefully removed by inverting the plate over a piece of tissue paper. After the last wash, each well was aspirated quickly to remove all residual PBS. The plate was placed on dry ice, and 500 µl of extraction buffer was added per 1,000,000 cells. The plate was gently swirled such that cells were covered by the extraction buffer. The plate was incubated for 20 min on a dry ice–methanol bath to break cell membranes. The cells were scraped off the plate and the entire suspension was transferred into prechilled Eppendorf tubes. The cell-extract suspension was shaken for 15 min at 4 °C in a Thermomixer at maximum speed (Thermomixer set at 4 °C and placed in a cold room for this step). The tubes were then centrifuged for 20 min at 4 °C at maximum speed (13,000 r.p.m. or higher). Only the top 80% of the supernatant was collected and put into prelabelled autosampler vials, taking care not to disturb the solid debris. A pooled sample was prepared by taking 10 µl of each sample from the same matrix. Samples were stored at –80 °C until further analysis.

Metabolite extraction from cell culture medium

Eighty microliters of cell culture medium was taken and centrifuged for 5 min (4 °C) at maximum speed to eliminate dead cells. Fifty microliters of the supernatant was taken and added to a prelabelled Eppendorf tube containing 350 µl of extraction solution on dry ice. The samples

were mixed for 15 min in a Thermomixer at 4 °C at maximum speed, followed by centrifugation for 20 min at 4 °C at maximum speed (13,000 r.p.m. or higher). The top 80% of the supernatant was carefully transferred into an autosampler vial, taking care not to disturb the insoluble debris. A pooled sample was prepared by mixing equal volumes of each sample extract in a single vial. Samples were stored at –80 °C until further analysis.

Liquid chromatography coupled to mass spectrometry

Hydrophilic interaction chromatographic (HILIC) separation of the targeted metabolite (2HG) was achieved using a Millipore Sequant ZIC-pHILIC analytical column (5 µm, 2.1×150 mm) equipped with a 2.1×20-mm guard column (both 5-mm particle size) with a binary solvent system. Solvent A was 20 mM ammonium carbonate, 0.05% ammonium hydroxide; Solvent B was ACN. The column oven and autosampler tray were held at 40 °C and 4 °C, respectively. The chromatographic gradient was run at a flow rate of 0.200 ml min^{–1} as follows: 0–2 min, 80% B; 2–17 min, linear gradient from 80% B to 20% B; 17–17.1 min, linear gradient from 20% B to 80% B; 17.1–23 min, hold at 80% B. Samples were randomized, and the injection volume was 5 µl. A pooled quality control sample was generated from an equal mixture of all individual samples and analysed interspersed at regular intervals. Metabolites were measured with Vanquish Horizon UHPLC coupled to an Orbitrap Exploris 240 mass spectrometer (both Thermo Fisher Scientific) using a heated electrospray ionization source. The spray voltages were set to –2.8 kV, the RF lens value was set at 70, the heated capillary was held at 320 °C and the auxiliary gas heater was held at 280 °C. The flow rate for sheath gas, aux gas and sweep gas were set to 40, 15 and 0, respectively. For MS1 scans, the mass range was set to m/z = 100–600, AGC target set to standard and maximum injection time set to auto. Data acquisition for experimental samples used full scan and selected ion monitoring (SIM) modes (targeting 2HG m/z = 147.0299) at an Orbitrap resolution of 120,000 in negative mode.

Targeted metabolomics for 2HG quantification

The identity of metabolite 2HG was verified based on two criteria: (1) the precursor ion m/z corresponded to within 3 p.p.m. of the expected mass derived from its chemical structure, and (2) the retention duration was within a 5% range compared with that of a purified reference sample analysed using the identical chromatography technique. The examination of chromatograms and integration of peak areas was carried out using the Tracefinder software (v5.1, Thermo Fisher Scientific). The peak area of each identified metabolite was adjusted on the basis of the total ion count of the respective sample to compensate for any discrepancies arising from sample preparation or instrument assessment. These measurements were done in collaboration with the Frezza lab at the CECAD Research Center.

Chiral derivatization of 2HG

TSPC derivatization was performed for LC–electrospray ionization–tandem MS (LC–ESI–MS/MS) analysis, under optimized conditions. Tissue supernatant was dried under nitrogen gas at 37 °C, resuspended in TSPC (2.5 mM in ACN) and pyridine and derivatized. The mixture was dried again, redissolved in 50% aqueous ACN containing phthalic acid, and 10 µl was injected into the LC–ESI–MS/MS system.

Liquid chromatography–electrospray ionization–tandem mass spectrometry analysis. Quantification of TSPC-labeled D-2HG and L-2HG was performed on an AB 3200 QTRAP mass spectrometer (Applied Biosystems) coupled to a Shimadzu LC-20AD HPLC. HPLC separation was conducted using an Inertsil ODS-3 column (250 × 2.0 mm, 5 µm) at 35 °C, with a formic acid–water (0.1%) and ACN–methanol (50:50) gradient at 0.2 ml min^{–1}. Detection was performed with multiple reaction monitoring in negative-ion mode with optimized transitions for

2HG and phthalic acid. For comparison, the derivatization of D-2HG and L-2HG with diacetyl-L-tartaric anhydride (DATAN) was also performed, and the detailed procedure has been previously published⁶⁶. Additional HR–MS experiments were conducted on a MicroTOF-Q mass spectrometer (Bruker Daltonics) with an ESI source, using optimized parameters for maximal detection sensitivity.

Cholesterol quantification in mature brown adipocytes through ILC–ESI–MS/MS

Cholesterol levels in mBAs were determined using LC–ESI–MS/MS. Adipose tissue was homogenized in Milli-Q water using a Precellys 24 Homogenizer, and protein content was measured using the Bradford assay. Lipids were extracted using the one-step extraction method⁶⁷. For extraction, homogenized samples were mixed with chloroform, methanol, hydrochloric acid and cholesterol-d7 (internal standard). Lipid extracts were dried under nitrogen, resuspended in ammonium acetate in methanol, sonicated and centrifuged. Supernatants were analysed via LC–ESI–MS/MS using a Core-Shell Kinetex C18 column on a QTRAP 6500 mass spectrometer (AB SCIEX). UHPLC was performed isocratically with a 5 mM ammonium acetate–methanol mobile phase at 300 µl min^{–1}. Cholesterol and cholesterol-d7 were detected in positive-ion mode using multiple reaction monitoring transitions. Endogenous cholesterol was quantified using an external calibration curve, normalized to protein content, and analysed with MultiQuant 3.0.3 software.

Statistical analysis

Statistical significance was evaluated using tests appropriate for the distribution and design of each experiment. Depending on the context, paired two-tailed Student's *t*-tests, one-way ANOVA or Kolmogorov–Smirnov tests were applied, as specified in the individual figure legends. Error bars indicate the s.d. unless otherwise noted. Statistical significance is reported as *P* values, denoted by asterisks ($P < 0.05$, * $P < 0.01$, ** $P < 0.001$, *** $P < 0.0001$) or symbols (for example, ## $P < 0.001$), as defined in the figure legends. Unless stated otherwise, experiments were independently repeated at least three times to ensure reproducibility. Sample numbers indicated in figure legends refer to the number of replicates shown, not the total number of biological replicates in the study, with the exception of cell culture experiments. For all the cell culture experiments, *n* in the figure legends indicates the number of cells or nuclei analysed, from five independent wells for each experiment. No statistical methods were used to predetermine sample sizes, but sample sizes are consistent with those used in comparable published studies.

Data collection and randomization

Mice or cell culture samples or dishes were randomly assigned to experimental groups. Data collection and outcome assessments were performed in a randomized manner, when applicable. Experimental conditions and sample processing were organized to minimize bias, with randomization applied during sample allocation and data acquisition. The data distribution was assumed to be normal but this was not formally tested. Researchers performing data collection and analysis were not blinded to experimental conditions.

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Data availability

Raw data for BAT tissue transcriptomics are publicly available from the Gene Expression Omnibus (GEO) under the accession number [GSE271207](#); cell transcriptomics data are publicly available under the accession number [GSE271358](#). All raw data related to proteomics experiments on BAT tissue and mBA cells are publicly available under the accession number [PXD064288](#). All raw data for metabolomics

from BAT tissue and cells are publicly available in the Zenodo repository (<https://doi.org/10.5281/zenodo.15357452>)⁶⁸. Raw data from the ChIP-seq experiment using mBA cells is publicly available under the accession number [GSE296541](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296541). The following reference genomes were used in the manuscript: GRCm39 mouse reference genome and Gen-code vM25. Source data are provided with this paper.

Code availability

All analyses were performed using standard software packages as described in the Methods. The custom codes used in this study are available from the corresponding author upon request.

References

- Siekevitz, P. Powerhouse of the cell. *Sci. Am.* **197**, 131–144 (1957).
- Monzel, A. S., Enriquez, J. A. & Picard, M. Multifaceted mitochondria: moving mitochondrial science beyond function and dysfunction. *Nat. Metab.* **5**, 546–562 (2023).
- Murphy, M. P. & Hartley, R. C. Mitochondria as a therapeutic target for common pathologies. *Nat. Rev. Drug Discov.* **17**, 865–886 (2018).
- Eisner, V., Picard, M. & Hajnoczky, G. Mitochondrial dynamics in adaptive and maladaptive cellular stress responses. *Nat. Cell Biol.* **20**, 755–765 (2018).
- Bao, X. R. et al. Mitochondrial dysfunction remodels one-carbon metabolism in human cells. *eLife* **5**, e10575 (2016).
- Kaspar, S. et al. Adaptation to mitochondrial stress requires CHOP-directed tuning of ISR. *Sci. Adv.* **7**, eabf0971 (2021).
- Ahola, S. et al. OMA1-mediated integrated stress response protects against ferroptosis in mitochondrial cardiomyopathy. *Cell Metab.* **34**, 1875–1891 (2022).
- Altshuler-Keylin, S. & Kajimura, S. Mitochondrial homeostasis in adipose tissue remodeling. *Sci. Signal.* **10**, eaai9248 (2017).
- Rosen, E. D. & Spiegelman, B. M. What we talk about when we talk about fat. *Cell* **156**, 20–44 (2014).
- Cypess, A. M. & Kahn, C. R. Brown fat as a therapy for obesity and diabetes. *Curr. Opin. Endocrinol. Diabetes Obes.* **17**, 143–149 (2010).
- Maurer, S., Harms, M. & Boucher, J. The colorful versatility of adipocytes: white-to-brown transdifferentiation and its therapeutic potential in humans. *FEBS J.* **288**, 3628–3646 (2021).
- Cairo, M. et al. Parkin controls brown adipose tissue plasticity in response to adaptive thermogenesis. *EMBO Rep.* **20**, e46832 (2019).
- Schlein, C. et al. Endogenous fatty acid synthesis drives brown adipose tissue involution. *Cell Rep.* **34**, 108624 (2021).
- Shimizu, I. et al. Vascular rarefaction mediates whitening of brown fat in obesity. *J. Clin. Invest.* **124**, 2099–2112 (2014).
- Sass, F. et al. TFEB deficiency attenuates mitochondrial degradation upon brown adipose tissue whitening at thermoneutrality. *Mol. Metab.* **47**, 101173 (2021).
- Kuipers, E. N. et al. A single day of high-fat diet feeding induces lipid accumulation and insulin resistance in brown adipose tissue in mice. *Am. J. Physiol. Endocrinol. Metab.* **317**, E820–E830 (2019).
- Kotzbeck, P. et al. Brown adipose tissue whitening leads to brown adipocyte death and adipose tissue inflammation. *J. Lipid Res.* **59**, 784–794 (2018).
- Lee, J., Ellis, J. M. & Wolfgang, M. J. Adipose fatty acid oxidation is required for thermogenesis and potentiates oxidative stress-induced inflammation. *Cell Rep.* **10**, 266–279 (2015).
- Funda, J. et al. Adipose tissue-specific ablation of PGC-1 β impairs thermogenesis in brown fat. *Dis. Model. Mech.* **15**, dmm049223 (2022).
- Seale, P. et al. Transcriptional control of brown fat determination by PRDM16. *Cell Metab.* **6**, 38–54 (2007).
- Ziqubu, K. et al. An insight into brown/beige adipose tissue whitening, a metabolic complication of obesity with the multifactorial origin. *Front Endocrinol.* **14**, 1114767 (2023).
- Pereira, R. O. et al. OPA1 deletion in brown adipose tissue improves thermoregulation and systemic metabolism via FGF21. *eLife* **10**, e66519 (2021).
- Mahdavian, K. et al. Mfn2 deletion in brown adipose tissue protects from insulin resistance and impairs thermogenesis. *EMBO Rep.* **18**, 1123–1138 (2017).
- Vernochet, C. et al. Adipose tissue mitochondrial dysfunction triggers a lipodystrophic syndrome with insulin resistance, hepatosteatosis, and cardiovascular complications. *FASEB J.* **28**, 4408–4419 (2014).
- Becker, C. et al. CLPP deficiency protects against metabolic syndrome but hinders adaptive thermogenesis. *EMBO Rep.* **19**, e45126 (2018).
- Qiu, J. et al. FAM210A is essential for cold-induced mitochondrial remodeling in brown adipocytes. *Nat. Commun.* **14**, 6344 (2023).
- Takasugi, M. et al. An atlas of the aging mouse proteome reveals the features of age-related post-transcriptional dysregulation. *Nat. Commun.* **15**, 8520 (2024).
- Xiao, H. et al. Architecture of the outbred brown fat proteome defines regulators of metabolic physiology. *Cell* **185**, 4654–4673 (2022).
- Szczepanowska, K. et al. CLPP coordinates mitochondrial assembly through the regulation of ERAL1 levels. *EMBO J.* **35**, 2566–2583 (2016).
- Eguchi, J. et al. Transcriptional control of adipose lipid handling by IRF4. *Cell Metab.* **13**, 249–259 (2011).
- Turpin, S. M. et al. Obesity-induced CerS6-dependent C-16:0 ceramide production promotes weight gain and glucose intolerance. *Cell Metab.* **20**, 678–686 (2014).
- Huang da, W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nat. Protoc.* **4**, 44–57 (2009).
- Torres-Odio, S. et al. Loss of mitochondrial protease CLPP activates type I IFN responses through the mitochondrial DNA–cGAS–STING signaling axis. *J. Immunol.* **206**, 1890–1900 (2021).
- Shamsi, F., Zheng, R., Ho, L. L., Chen, K. & Tseng, Y. H. Comprehensive analysis of intercellular communication in the thermogenic adipose niche. *Commun. Biol.* **6**, 761 (2023).
- Roh, H. C. et al. Warming induces significant reprogramming of beige, but not brown, adipocyte cellular identity. *Cell Metab.* **27**, 1121–1137 (2018).
- Duteil, D. et al. Lsd1 ablation triggers metabolic reprogramming of brown adipose tissue. *Cell Rep.* **17**, 1008–1021 (2016).
- Benador, I. Y. et al. Mitochondria bound to lipid droplets have unique bioenergetics, composition, and dynamics that support lipid droplet expansion. *Cell Metab.* **27**, 869–885 (2018).
- Rzem, R., Vincent, M. F., Van Schaftingen, E. & Veiga-da-Cunha, M. L-2-hydroxyglutaric aciduria, a defect of metabolite repair. *J. Inher. Metab. Dis.* **30**, 681–689 (2007).
- Intlekofer, A. M. et al. L-2-Hydroxyglutarate production arises from noncanonical enzyme function at acidic pH. *Nat. Chem. Biol.* **13**, 494–500 (2017).
- Fan, J. et al. Human phosphoglycerate dehydrogenase produces the oncometabolite D-hydroxyglutarate. *ACS Chem. Biol.* **10**, 510–516 (2015).
- Dang, L. et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. *Nature* **462**, 739–744 (2009).
- Pacold, M. E. et al. A PHGDH inhibitor reveals coordination of serine synthesis and one-carbon unit fate. *Nat. Chem. Biol.* **12**, 452–458 (2016).

43. Kusi, M. et al. 2-Hydroxyglutarate destabilizes chromatin regulatory landscape and lineage fidelity to promote cellular heterogeneity. *Cell Rep.* **38**, 110220 (2022).
44. Lefterova, M. I., Haakonsson, A. K., Lazar, M. A. & Mandrup, S. PPAR γ and the global map of adipogenesis and beyond. *Trends Endocrinol. Metab.* **25**, 293–302 (2014).
45. Madison, B. B. Srebp2: a master regulator of sterol and fatty acid synthesis. *J. Lipid Res.* **57**, 333–335 (2016).
46. Hames, K. C., Vella, A., Kemp, B. J. & Jensen, M. D. Free fatty acid uptake in humans with CD36 deficiency. *Diabetes* **63**, 3606–3614 (2014).
47. Pohnl, M., Trollmann, M. F. W. & Bockmann, R. A. Nonuniversal impact of cholesterol on membranes mobility, curvature sensing and elasticity. *Nat. Commun.* **14**, 8038 (2023).
48. Baird, M. A. et al. Lamin B receptor upregulation in metastatic melanoma causes cholesterol-mediated nuclear envelope fragility. Preprint at *bioRxiv* <https://doi.org/10.1101/2023.12.21.572889> (2023).
49. Lee, M. D. et al. Human mitochondrial peptide deformylase, a new anticancer target of actinonin-based antibiotics. *J. Clin. Invest.* **114**, 1107–1116 (2004).
50. Trifunovic, A. et al. Premature ageing in mice expressing defective mitochondrial DNA polymerase. *Nature* **429**, 417–423 (2004).
51. Bean, C. et al. The mitochondrial protein Opa1 promotes adipocyte browning that is dependent on urea cycle metabolites. *Nat. Metab.* **3**, 1633–1647 (2021).
52. Enkler, L. & Spang, A. Functional interplay of lipid droplets and mitochondria. *FEBS Lett.* **598**, 1235–1251 (2024).
53. Nguyen, T. B. et al. DGAT1-dependent lipid droplet biogenesis protects mitochondrial function during starvation-induced autophagy. *Dev. Cell* **42**, 9–21 (2017).
54. Jackson, C. B. et al. De novo serine biosynthesis is protective in mitochondrial disease. *Cell Rep.* **44**, 115710 (2025).
55. Garcia, I., Cornely, K., Peterson, C. N. & Berkmen, M. B. Roles of the oncometabolite enantiomers of 2-hydroxyglutarate and their metabolism by diverse dehydrogenases. *Essays Biochem.* **68**, 161–171 (2024).
56. Lu, C. et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. *Nature* **483**, 474–478 (2012).
57. Notarangelo, G. et al. Oncometabolite d-2HG alters T cell metabolism to impair CD8⁺ T cell function. *Science* **377**, 1519–1529 (2022).
58. Desai, R. et al. Mitochondria form contact sites with the nucleus to couple prosurvival retrograde response. *Sci. Adv.* **6**, eabc9955 (2020).
59. Romanauska, A. & Kohler, A. Lipid saturation controls nuclear envelope function. *Nat. Cell Biol.* **25**, 1290–1302 (2023).
60. Ghose, R. et al. Mitochondria-derived nuclear ATP surge protects against confinement-induced proliferation defects. Preprint at *bioRxiv* <https://doi.org/10.1101/2023.12.20.572417> (2023).
61. Miroshnikova, Y. A. & Wickstrom, S. A. Mechanical forces in nuclear organization. *Cold Spring Harb. Perspect. Biol.* **14**, a039685 (2022).
62. Nava, M. M. et al. Heterochromatin-driven nuclear softening protects the genome against mechanical stress-induced damage. *Cell* **181**, 800–817 (2020).
63. Bhardwaj, V. et al. snakePipes: facilitating flexible, scalable and integrative epigenomic analysis. *Bioinformatics* **35**, 4757–4759 (2019).
64. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc. Natl Acad. Sci. USA* **102**, 15545–15550 (2005).
65. Robinson, J. T. et al. Integrative genomics viewer. *Nat. Biotechnol.* **29**, 24–26 (2011).
66. Cheng, Q.-Y. et al. Sensitive determination of onco-metabolites of D- and L-2-hydroxyglutarate Enantiomers by Chiral Derivatization Combined with Liquid Chromatography/mass Spectrometry Analysis. *Sci. Rep.* **5**, 15217 (2015).
67. Ozbalci, C., Sachsenheimer, T. & Brugger, B. Quantitative analysis of cellular lipids by nano-electrospray ionization mass spectrometry. *Methods Mol. Biol.* **1033**, 3–20 (2013).
68. Kaul, H. et al. 2-hydroxyglutarate mediates whitening of brown adipocytes coupled to nuclear softening upon mitochondrial dysfunction [Data set]. *Zenodo* <https://doi.org/10.5281/zenodo.15357452> (2025).

Acknowledgements

We are grateful to M. Yang, A. Sokol and D. Prymidis for assistance with metabolomics experiments and analysis; C. Jüngst, B. Martiny and P. Zentis and the CECAD Imaging Facility; J.-W. Lackmann and the CECAD Proteomics facility; to R. J. Acton and the CECAD Bioinformatics Facility; S. Brodesser and the CECAD lipidomics facility; N. Oikonomou and the CECAD FACS facility; and the Cologne Center for Genomics (CCG) for excellent technical assistance. Research reported in this publication was supported by funding to A.T. from the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) SFB1218 (project no. 269925409) and TR1018/8-1. C.F. is supported by a Cancer Research UK (CRUK) Programme Foundation Award (PFA; C51061/A27453), a European Research Council (ERC) Consolidator Grant (ONCOFUM, ERC819920) and the Alexander von Humboldt Foundation in the framework of an Alexander von Humboldt Professorship endowed by the Federal Ministry of Education and Research. S.A.W. is supported by Academy of Finland R'Life Programme consortium NucleoMech, Helsinki Institute of Life Science, and the Max Planck Society. N.P. is supported by Deutsche Forschungsgemeinschaft SFB1403 grant 414786233 (A10).

Author contributions

H.K. and A.T. conceived the study and together with J.C.B., M.L., A.P., T.L., N.P., S.A.W. and C.F. designed the experiments. H.K., K. Senft, L.I., L.B., P.S., B.L., X.H. and T. Gnad performed and analysed various in vivo, cell and molecular biology experiments. H.K., J.H.P., U.G., H.N., M.P. and J.-W.K. performed and analysed the RNA-seq experiments. H.K., U.G. and A.T. performed and analysed the proteomics experiments. H.K., M.C. and T. Georgomanolis performed and analysed the metabolomics experiments. H.K., T. Georgomanolis and A.P. performed and analysed the ChIP-seq experiments. H.K., F.P. and S.W. performed and analysed the AFM measurements. H.K., K. Seidel, F.G. and A.S. performed, analysed and modelled the electron microscopy experiments. A.T., C.F., S.W., T.L., N.P. and M.L. supervised the experiments. H.K. and A.T. interpreted data and wrote the paper.

Funding

Open access funding provided by Universität zu Köln.

Competing interests

The authors declare no competing interests.

Additional information

Extended data is available for this paper at <https://doi.org/10.1038/s42255-025-01332-8>.

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s42255-025-01332-8>.

Correspondence and requests for materials should be addressed to Aleksandra Trifunovic.

Peer review information *Nature Metabolism* thanks Luca Scorrano, Navdeep Chandel and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Primary Handling Editor: Revati Dewal, in collaboration with the *Nature Metabolism* team.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing,

adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2025


¹Institute for Mitochondrial Diseases in Ageing, Faculty of Medicine, University of Cologne, and University Hospital Cologne, Cologne, Germany.

²Cologne Excellence Cluster on Cellular Stress Responses in Ageing-Associated Diseases (CECAD), University of Cologne, Cologne, Germany. ³Institute for Metabolomics in Ageing, Faculty of Medicine, University of Cologne, and University Hospital Cologne, Cologne, Germany. ⁴Max Planck Institute for Biology of Ageing, Cologne, Germany. ⁵Department of Infectious Diseases, Center for Integrative Infectious Disease Research (CIID), Integrative Virology, Heidelberg University, Heidelberg, Germany. ⁶Department of Genome Editing, Institute of Biomedical Genetics (IBMG), University of Stuttgart, Stuttgart, Germany. ⁷Centre for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany. ⁸Bonn University Hospital (AöR), Biomedical Center (BMZ), Bonn, Germany. ⁹Federal Institute for Drugs and Medical Devices, Bonn, Germany. ¹⁰Department of Cell and Tissue Dynamics, Max Planck Institute for Molecular Biomedicine, Münster, Germany. ¹¹Department of Neuronal Control of Metabolism, Max Planck Institute for Metabolism Research, and Center for Endocrinology, Diabetes and Preventive Medicine (CEDP), University Hospital Cologne, Cologne, Germany. ¹²University of Southern Denmark, Odense, Denmark. ¹³Stem Cells and Metabolism Research Program, Faculty of Medicine and Helsinki Institute of Life Science, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland. ¹⁴Institute of Genetics Faculty of Mathematics and Natural Sciences, University of Cologne, Cologne, Germany. ✉ e-mail: aleksandra.trifunovic@uk-koeln.de



Extended Data Fig. 1 | Effects of CLPP loss show similar changes in AKO and BKO. (a) Immunoblot of CLPP from wild type (WT), ubiquitously-deficient CLPP mice (KO), adipose-specific CLPP KO (AKO) or BAT specific CLPP KO (BKO) mice ($n = 3$, blots representative of four independent experiments); **(b)** H&E staining of BAT from WT, KO, AKO and BKO mice, scale bar = $200\mu\text{m}$ (images represent results from three animals per genotype); **(c)** Gain in body weight with age in AKO and BKO male and female mice, ($n = 11$ and 12 male of WT and AKO respectively, 10 and 6 female of WT and AKO respectively, $n = 6$ and 5 male of WT and BKO respectively, 6 and 7 female of WT and BKO respectively); **(d-e)** In-gel activity

assay for **(d)** Complex I (CI) and **(e)** Complex V (CV) in WT, KO, AKO and BKO mice, ($n = 3$); **(f)** Quantification of lipolysis (glycerol release) in BAT of WT and KO mice under baseline (control) and stimulated conditions ($n = 3$); **(g)** Oil red O staining of WT and KO mBA cells (images represent results from three independent experiments). **(h)** Relative steady-state protein levels (log2) as obtained by label-free proteomics analysis of WT and KO preadipocytes and differentiated WT and KO mBA cells ($n = 3$); **(f and h)** Data are presented as mean $\pm$ SD. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$ as determined by One-way ANOVA with multiple comparisons.




Extended Data Fig. 2 | CLPP loss in BAT shows no immune or developmental changes. (a) Flow cytometry analysis of immune cells profile in the BAT from BAT specific CLPP KO (BKO) mice ($n = 5$); (b) Flow cytometry analysis of immune cells profile from bone marrow of BKO mice, graphs showing quantification of (left to right) lymphoid cells, hematopoietic progenitor cells, monocytes and mentioned progenitor cells ($n = 5$); (c) (left) Representative pipeline for deconvolution analysis followed; (right) Deconvoluted bulk RNA Seq data from BAT of ubiquitously-deficient CLPP mice (KO) mice, represented as UMAPs,

with cell populations marked in different colours; (d) Relative proportions of designated cell types from deconvolution, reveals no quantitative differences in muscle cell population; (e) Comparison of BAT transcriptome from CLPP BKO to gene expression changes observed in BAT whitening models induced either by (left) BAT specific loss of LSD1 or (right) by thermoneutral temperatures. (a and b) Data are presented as mean $\pm$ SEM * $p < 0.05$, as determined by One-way ANOVA with multiple comparisons in a and b. Schematic created using BioRender.com.



Extended Data Fig. 3 | Isolated mitochondria from KO BAT have OXPHOS deficiency. **(a)** Heatmap of significantly changed protein abundances of mitochondrial proteins from BAT tissue of wild type (WT) and brown adipose specific CLPP deficient (BKO) mice. **(b)** Heat map of significantly changed protein abundances of mitochondrial proteins from isolated cytoplasmic and peri lipid droplet mitochondria of WT and ubiquitously-deficient CLPP mice (KO) mice, full table can be seen in Supplementary Table 4; **(c)** Steady-state levels of OXPHOS supercomplexes (SC) in BAT cytoplasmic (CM) or peri lipid droplet


(PDM) mitochondria of WT and CLPP KO mice, analysed by BN-PAGE followed by western blot for **(left)** CI (NDUFA9) and **(middle)** CIII (UQCRC1) and **(right)** CV (ATP5A) (n = 3); **(d)** Relative fold changes of subunits of OXPHOS complexes in isolated CM from BAT and whole BAT tissue lysates, (n = 3 for CM and n = 4 for WTL). **(d)** Data are presented as mean $\pm$ SD. Red text colour represents complexes which were significantly changed in isolated cytoplasmic mitochondria and red text with # represents complexes significantly changed compared to whole BAT tissue lysates, as determined by paired two-tailed Student's t-test in **d**.



Extended Data Fig. 4 | See next page for caption.

Extended Data Fig. 4 | 2-HG accumulates in BAT and is potentially produced by PHGDH. **(a)** Volcano plot of significantly changed metabolites in CLPP deficient (KO) mBA cells compared to wild type (WT) cells (n = 5), dark colored dots present significantly changed metabolites ($p \leq 0.01$, two-fold-change); **(b)** Relative transcript abundances of PHGDH in BAT from ubiquitously-deficient (KO), adipose-specific (AKO) or BAT specific (BKO) CLPP KO mice, compared to the wild type wild type (WT) (n = 4); **(c)** Immunoblot and quantification of steady state levels of PHGDH from WT and KO mBA cells (n = 3, western blot analysis was repeated with additional three independent samples/group); **(d)** Quantification of PHGDH enzymatic activity (n = 5) **(e)** Relative percentages of 2HG D and L isoforms in WT and CLPP KO mBA cells, as assessed by the derivatization of 2HG using TSCP (n = 5); **(f)** Quantification of 2HG by targeted metabolomics in KO, D2HGDH overexpressing KO (KO + D2HGDH), NCT503 treated KO (KO + NCT) and NCT503 treated KO + D2HGDH (KO + D2HGDH + NCT) mBA cells, (n = 5);

(g) Lipid levels in wild type (WT), D2HGDH overexpressing WT (WT + D2HGDH), KO and KO + D2HGDH mBA cells, normalized to the average of the MFI value of the WT cells (n = 11,11,11,14 respectively); **(h)** Immunoblot of steady state levels of ISR proteins from wild type (WT), ISRIB treated WT (WT + ISRIB), KO and ISRIB-treated KO (KO + ISRIB) mBA cells (n = 3) (blots representative of three independent experiments); **(i)** Quantification of 2HG by targeted metabolomics from WT, KO and KO + ISRIB mBA cells (n = 5); **(j)** Lipid levels in WT, WT + ISRIB, KO and KO + ISRIB mBA cells, normalized to the average of the MFI value of the WT cells (n = 4). **(b-g, i-j)** Data are presented as mean $\pm$ SD. * $p < 0.05$, *** $p < 0.001$, **** $p < 0.0001$, as determined by One-way ANOVA with multiple comparisons in **b, e, f, h** and **i** and Students paired two tailed t-test in **d**; ** $p < 0.001$ represent significant difference in the ratio between D- and L-forms between WT and KO, as determined by Students paired two tailed t-test.




Extended Data Fig. 5 | See next page for caption.

Extended Data Fig. 5 | Omics analysis shows remodelling of mBA cells

upon treatments. **(a)** Immunoblot of steady state levels of indicated histone modifications in wild type (WT), D-2HG treated WT (WT + HG) and CLPP deficient (KO) mBA cells, (right) quantification of levels of the histone marks normalized to H3 from the immunoblots, ($n = 3$); **(b)** Single nuclei intensity quantitation of histone marks in untreated WT, WT + HG and KO mBA ($n = 798$ for WT, $n = 825$ for WT + HG and $n = 1088$ for KO, collectively obtained from three individual cell culture plates); **(c)** Peak count frequency profile depicting enrichment of H3K4me3 peaks from CHIP Seq of WT, KO and WT + HG mBA cells relative to the TSS; **(d)** Feature distribution bar plot depicting relative proportions

of genomic regions enriched in H3K4me3 in WT, KO and WT + HG mBA cells; **(e)** Relative mRNA levels of genes involved in lipid transport in CLPP KO cells. Untreated WT cells, and cells treated with D-2HG are used as controls ($n = 3$); **(f)** GSEA enrichment plots for gene signatures related to sterol biosynthesis in mBA cells and BAT tissue of KO mice compared to WT. **(a, e)** Data are presented as mean $\pm$ SD. **(b)** Data are presented using Tukey's box plot with middle line marking the median, and whiskers show variability within $1.5 \times \text{IQR}$. Anything beyond is an outlier presented as individual value. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$, as determined by One-way ANOVA with multiple comparisons in **a**, **b** and **e**.



Extended Data Fig. 6 | Nuclear architecture changes upon CLPP loss in BAT. (a) Venn diagram representing GO:CC analysis of common differentially expressed genes in CLPP deficient (KO) and 2HG treated WT (WT + HG) cells compared to untreated wild type (WT) mBA cells; (b) GSEA enrichment plots for gene signatures related to nuclear lamina in both KO mBA cells and KO BAT tissue compared to WT; (c) Representative TEM images showing mitochondria impinging on the nucleus and juxtaposed to nuclear pores (images represent results observed in 19 TEM sections from KO BAT of three animals);

(d) Quantitation of the number of ER sites spotted in TEM images from WT and KO mice, represented as percentage of the total number of fields assessed; (e) Quantification of Young's modulus in KO and ISRIB-treated KO mBA nuclei ($n = 110$ for KO, $n = 120$ for KO + ISRIB and $n = 1088$ for KO, collectively obtained from three individual cell culture plates). (e) Data are presented using Tukey's box plot with middle line marking the median, and whiskers show variability within $1.5 \times \text{IQR}$. Anything beyond is an outlier presented as individual value. No significant differences were observed as assessed by paired two-tailed Student's t -test.

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a	Confirmed
☐	☒ The exact sample size (<i>n</i>) for each experimental group/condition, given as a discrete number and unit of measurement
☐	☒ A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
☐	☒ The statistical test(s) used AND whether they are one- or two-sided <i>Only common tests should be described solely by name; describe more complex techniques in the Methods section.</i>
☒	☐ A description of all covariates tested
☐	☒ A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
☐	☒ A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
☐	☒ For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
☒	☐ For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
☒	☐ For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
☒	☐ Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection	Histological images were collected by using a slide scanner S360, Hamamatsu Slidescanner with Autoloader. Immunofluorescence images were obtained using LSM 980 with Airyscan 2 and multiplex, Carl Zeiss Microscopy, TCS SP8, Leica Microsystems, and LSM Meta 710, Carl Zeiss Technology. Electron microscopy images were captured by a transmission electron microscope (JOEL JEM2100 Plus) at an acceleration voltage of 80 kV, using a 4K-CCD camera, OneView (GATAN). The rt-PCR data was collected by QuantStudio 12K Flex Software v1.6 (Applied Biosystems) Metabolomics data was collected by Thermo Scientific Q Exactive Hybrid Quadrupole-Orbitrap Mass spectrometer (HRMS) coupled to a Dionex Ultimate 3000 UHPLC, Orbitrap Eclipse Tribrid Mass Spectrometer (Thermo Fischer Scientific). Proteomics data was collected by liquid chromatography tandem mass spectrometry on an Orbitrap Eclipse Tribrid Mass Spectrometer (Thermo Fischer) with FAIMS Pro device. PHGDH activity assay OD were measured in EnSpire plate reader. For ChIP seq, libraries were prepared using KAPA Library Quantification kit (Peqlab) and the 7900HT Sequence Detection System (Applied Biosystems) The pools were sequenced on an Illumina NovaSeq6000 sequencing instrument
Data analysis	GraphPad Prism 10 for MacOS ImageJ2 2.9.0/1.53t Microsoft Excel for Mac 16.75.2 FlowJo Software version 10.0.8 Seahorse Wave Desktop 2.6 software Seurat version 3.0 with R version 3.6.2

R package ComplexHeatmap version 2.12.1
 GSEA windows application v4.3.2 [build 13]
 UCell package version 2.0.1
 Diva software (BD)
 FlowJo version 10.0.8
 snakePipes version 2.8.1
 deeptools version 3.5.4
 samtools version 1.19.2
 fastqc version 0.12.1
 fastp version 0.23.4
 genrich version 0.6.1
 R version 4.4.2
 bedtools version 2.31.0

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

The following reference genomes were used in the manuscript - GRCm39 mouse reference genome (https://www.ncbi.nlm.nih.gov/datasets/genome/GCF_000001635.27/) and Gencode vM25 (https://www.gencodegenes.org/mouse/release_M25.html).

Raw data for BAT tissue transcriptomics is publicly available with the accession number - GSE271207, cell transcriptomics is publicly available with the accession number - GSE271358. All raw data related to proteomics experiments on BAT tissue and mBA cells are publicly available with the accession number PXD064288. All raw data for metabolomics from BAT tissue and cells is publicly available with the doi:10.5281/zenodo.15357452. Raw data from ChIP Seq experiment from mBA cells is publicly available with the accession number GSE296541.

Research involving human participants, their data, or biological material

Policy information about studies with [human participants or human data](#). See also policy information about [sex, gender \(identity/presentation\), and sexual orientation](#) and [race, ethnicity and racism](#).

Reporting on sex and gender

Reporting on race, ethnicity, or other socially relevant groupings

Population characteristics

Recruitment

Ethics oversight

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

☒ Life sciences ☐ Behavioural & social sciences ☐ Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size

Sample size was determined empirically and was based on our previous mouse work. We aimed for a number of at least 4 animals per group to allow basic statistical analysis while using justifiable number of mutant mice. All sample sizes were annotated within the respective Figure legends. Based on previous experience from similar studies, in vitro experiments with cultured cells were performed at least 3 times (3 biological replicates) to confirm reproducibility. For all experiments, biological replicates were used and each biological replicate is defined as an independent culture of cells.

Data exclusions	No animal data were excluded from the analyses.
Replication	For in vivo studies, we analyzed at least 6 mice per genotype to ensure the reproducibility of the results. For in vitro studies, we independently replicated the experiments at least 3 times.
Randomization	No specific method of randomization was used to select animals. We compared groups of mice with different genotypes to assess the effect of specific genetic mutations in the phenotype. Group allocation was thus determined by the genotype of the mice.
Blinding	Histological evaluation of BAT sections was performed blindly. Immunofluorescence imaging on cells was performed in a blinded manner. Metabolomic samples were analyzed with LC-MS in a blinded manner. For all other experiments, blinding was not relevant during the group generation as the group allocation was determined by the genotype of the mice.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

n/a	Involved in the study
☐	☒ Antibodies
☐	☒ Eukaryotic cell lines
☒	☐ Palaeontology and archaeology
☐	☒ Animals and other organisms
☒	☐ Clinical data
☒	☐ Dual use research of concern
☒	☐ Plants

Methods

n/a	Involved in the study
☐	☒ ChIP-seq
☐	☒ Flow cytometry
☒	☐ MRI-based neuroimaging

Antibodies

Antibodies used

Primary antibodies-

- 1) Monoclonal Anti-CLPP antibody (clone 300) produced in mouse, Cat No. WH0008192M1, Sigma Aldrich
- 2) HSPA8/HSC70 antibody (B-6), Cat No. sc-7298, Santa Cruz
- 3) NDUFA9 Monoclonal Antibody (20C11B11B11), Cat No 459100, ThermoFischer Scientific
- 4) SDHA Monoclonal Antibody (2E3GC12FB2AE2), Cat No 459200, ThermoFischer Scientific
- 5) ATP5A antibody [15H4C4] - Mitochondrial Marker
- 6) PHGDH Polyclonal antibody, Cat no : 14719-1-AP, Proteintech
- 7) Anti-Histone H3 (tri methyl K4) antibody - ChIP Grade, Cat no: ab8580
- 8) Anti-Histone H3 (tri methyl K36) antibody - ChIP Grade, Cat no: ab9050
- 9) Anti-Histone H3 (tri methyl K9) antibody - ChIP Grade, Cat no: ab8898
- 10) Tri-Methyl-Histone H3 (Lys27) (C36B11) Rabbit mAb, Cat no: 9733
- 11) Histone H3 trimethyl Lys4 antibody (pAb) - ChIP Grade, Cat no: 39159, Active Motif,
- 12) CD45 antibody (clone 30-F11), Cat No. 103107, BioLegend
- 13) B220 antibody (clone RA3-6B2), Cat No. 103223, BioLegend
- 14) CD115 antibody (clone AFS98), Cat No. 135517, BioLegend
- 15) CD117 antibody (clone ack2), Cat No. 135119, BioLegend
- 16) CD11b antibody (clone M1/70), Cat No. 612977, BD
- 17) CD11c antibody (clone HL3), Cat No. 564080, BD
- 18) CD127 (IL-7Rα) antibody (clone A7R34), Cat No. 135021, BioLegend
- 19) CD135 (clone A2F10) antibody, Cat No. 135305, BioLegend
- 20) CD16/32 (clone 93) antibody, Cat No. 101331, BioLegend
- 21) CD172a (SIRPα) (clone P84) antibody, Cat No. 144015, BioLegend
- 22) CD19 (clone 6D5) antibody, Cat No. 115529, BioLegend
- 23) CD34 (clone MEC14.7) antibody, Cat No. 119325, BioLegend
- 24) CD3E (clone 145-2C11) antibody, Cat No. 100329, BioLegend
- 25) CD45 (clone 30-F11) antibody, Cat No. 103127, BioLegend
- 26) CD49b (clone DX5) antibody, Cat No. 108919, BioLegend
- 27) F4/80 (clone T45-2342) antibody, Cat No. 749284, BD
- 28) Ly-6A/E (Sca-1) (clone D7) antibody, Cat No. 108137, BioLegend
- 29) MHCI (clone M5-114.15.2) antibody, Cat No. 107625, BioLegend
- 30) NK1.1 (clone PK136) antibody, Cat No. 108723, BioLegend
- 31) Ter119 (clone TER119) antibody, Cat No. 116223, BioLegend
- 32) TruStain FcX™ (anti-mouse CD16/32) (clone 93) antibody, Cat No. 101319, BioLegend

Secondary antibodies-

- 1) anti-mouse IgG peroxidase, Sigma Aldrich, order number: A4416
- 2) anti-rabbit IgG peroxidase, Sigma Aldrich, order number: A6154

Validation

The primary antibodies used in this study were tested by the manufacturer

- 1) anti-CLPP antibody can be found in 7 citations. The manufacturer also provides antibody testing data: <https://www.sigmaaldrich.com/DE/de/product/sigma/wh0008192m1>
- 2) anti-HSPA8/HSC70 antibody (B-6) antibody can be found in 7 citations. The manufacturer also provides antibody testing data: <https://www.scbt.com/p/hsc-70-antibody-b-6>
- 3) anti-NDUFA9 antibody can be found in 67 citations. The manufacturer also provides antibody testing data: <https://www.thermofisher.com/antibody/product/NDUFA9-Antibody-clone-20C11B11B11-Monoclonal/459100>
- 4) anti-SDHA antibody can be found in 94 citations. The manufacturer also provides antibody testing data: <https://www.thermofisher.com/antibody/product/SDHA-Antibody-clone-2E3GC12FB2AE2-Monoclonal/459200>
- 5) anti-ATP5A can be found in 376 citations. The manufacturer also provides antibody testing data: <https://www.abcam.com/en-de/products/primary-antibodies/atp5a-antibody-15h4c4-mitochondrial-marker-ab14748>
- 6) anti-PHGDH antibody can be found in 49 citations. The manufacturer also provides antibody testing data: <https://www.ptglab.com/products/PHGDH-Antibody-14719-1-AP.htm>
- 7) Anti-H3K4me3 antibody can be found in 2132 citations. The manufacturer also provides antibody testing data: https://www.abcam.com/en-us/products/primary-antibodies/histone-h3-tri-methyl-k4-antibody-chip-grade-ab8580?srsltid=AfmBOopn5dDbKHxVF_ncgG3Evsq0Je46EGo-kr1CmVgoy6-hB4DrdOGO
- 8) Anti-H3K36me3 antibody can be found in 11 citations, The manufacturer also provides antibody testing data: https://www.abcam.com/en-us/products/primary-antibodies/histone-h3-tri-methyl-k36-antibody-epr23525-232-chip-grade-ab282572?srsltid=AfmBOoiPi416tajU24h15yOcsVVVdIIKu01_W5KwHnkiPj_B6hhntEO
- 9) Anti H3K9me3 antibody can be found in 1735 citations, The manufacturer also provides antibody testing data- https://www.abcam.com/en-us/products/primary-antibodies/histone-h3-tri-methyl-k9-antibody-chip-grade-ab8898?srsltid=AfmBOor0sp0zz7BiTk65d2LHNAZ0dG2Y3sbtX4xGBZfaBoOQzBikvt_v
- 10) Anti H3K27me3 antibody can be found in 1545 citations, The manufacturer also provides antibody testing data- https://www.cellsignal.com/products/primary-antibodies/tri-methyl-histone-h3-lys27-c36b11-rabbit-mab/9733?srsltid=AfmBOooAUjv3GmXTBgeT_vSr-DISH0Hxle5RRhEUEPdwgwgNdhQ5ok7z
- 11) Anti H3K4me3 antibody used for CHIP can be found in 112 citations, The manufacturer also provides antibody testing data- <https://www.activemotif.com/catalog/details/39159/histone-h3-trimethyl-lys4-antibody-pab>
- 12) Anti CD45 antibody used in FACS can be found in 290 citations, The manufacturer provides antibody testing data- <https://www.biolegend.com/en-gb/products/fitc-anti-mouse-cd45-antibody-99?GroupID=BLG1932>
- 13) Anti B220 antibody can be found in 129 citations, The manufacturer provides antibody testing data- <https://www.biolegend.com/fr-lu/products/apc-cyanine7-anti-mouse-human-cd45r-b220-antibody-1938?GroupID=GROUP658>
- 14) Anti CD115 antibody can be found in 19 citations, The manufacturer provides antibody testing data- <https://www.biolegend.com/fr-ch/products/brilliant-violet-605-anti-mouse-cd115-csf-1r-antibody-9013>
- 15) Anti CD117 antibody can be found in 3 citations, The manufacturer provides antibody testing data- <https://www.biolegend.com/fr-fr/products/brilliant-violet-510-anti-mouse-cd117-c-kit-antibody-8482?GroupID=BLG8754>
- 16) Anti CD11b antibody can be found in 14 citations, The manufacturer provides antibody testing data- https://www.bdbiosciences.com/en-de/products/reagents/flow-cytometry-reagents/research-reagents/single-color-antibodies-ruo/buv661-rat-anti-cd11b.612977?tab=product_details
- 17) Anti CD11c antibody can be found in 18 citations, The manufacturer provides antibody testing data- https://www.bdbiosciences.com/en-de/products/reagents/flow-cytometry-reagents/research-reagents/single-color-antibodies-ruo/buv395-hamster-anti-mouse-cd11c.564080?tab=product_details
- 18) Anti CD127 antibody can be found in 16 citations, The manufacturer provides antibody testing data- <https://www.biolegend.com/de-at/products/percp-cyanine5-5-anti-mouse-cd127-il-7ralpha-antibody-6196>
- 19) Anti CD135 antibody can be found in 47 citations, The manufacturer provides antibody testing data- <https://www.biolegend.com/de-de/products/pe-anti-mouse-cd135-antibody-6173?GroupID=BLG7934>
- 20) Anti CD16/32 antibody can be found in 11 citations, The manufacturer provides antibody testing data- <https://www.biolegend.com/nl-be/products/brilliant-violet-421-anti-mouse-cd16-32-antibody-8598>
- 21) Anti CD172a antibody can be found in 4 citations, The manufacturer provides antibody testing data- <https://www.biolegend.com/de-de/products/pe-dazzle-594-anti-mouse-cd172a-sirpalpha-antibody-10804>
- 22) Anti CD19 antibody can be found in 110 citations, The manufacturer provides antibody testing data- <https://www.biolegend.com/en-ie/products/apc-cyanine7-anti-mouse-cd19-antibody-3903?GroupID=BLG2221>
- 23) Anti CD34 antibody can be found in 4 citations, The manufacturer provides antibody testing data- <https://www.biolegend.com/en-gb/products/pe-cyanine7-anti-mouse-cd34-antibody-14817>
- 24) Anti CD3E antibody can be found in 73 citations, The manufacturer provides antibody testing data- <https://www.biolegend.com/en-ie/products/apc-cyanine7-anti-mouse-cd3epsilon-antibody-6070?GroupID=BLG6746>
- 25) Anti CD45 antibody can be found in 214 citations, The manufacturer provides antibody testing data- <https://www.biolegend.com/de-de/products/alexa-fluor-700-anti-mouse-cd45-antibody-3407>
- 26) Anti CD49b antibody can be found in 12 citations, The manufacturer provides antibody testing data- <https://www.biolegend.com/en-gb/products/apc-cyanine7-anti-mouse-cd49b-pan-nk-cells-antibody-8057?GroupID=BLG4768>
- 27) Anti F4/80 antibody can be found in 3 citations, The manufacturer provides antibody testing data- https://www.bdbiosciences.com/en-de/products/reagents/flow-cytometry-reagents/research-reagents/single-color-antibodies-ruo/buv563-rat-anti-mouse-f4-80.749284?tab=product_details
- 28) Anti Ly-6A/E (Sca-1) antibody can be found in 1 citation, The manufacturer provides antibody testing data- <https://www.biolegend.com/de-at/products/pe-dazzle-594-anti-mouse-ly-6a-e-sca-1-antibody-10190>
- 29) Anti MHCII antibody can be found in 76 citations, The manufacturer provides antibody testing data- <https://www.biolegend.com/en-ie/products/percp-cyanine5-5-anti-mouse-i-a-i-e-antibody-4282>
- 30) Anti NK1.1 antibody can be found in 55 citations, The manufacturer provides antibody testing data- <https://www.biolegend.com/en-ie/products/apc-cyanine7-anti-mouse-nk-1-1-antibody-4002?GroupID=GROUP20>
- 31) Anti Ter119 antibody can be found in 67 citations, The manufacturer provides antibody testing data- <https://www.biolegend.com/en-gb/products/apc-cyanine7-anti-mouse-ter-119-erythroid-cells-antibody-3905>
- 32) Anti TruStain FcX™ (anti-mouse CD16/32) antibody can be found in 649 citations, The manufacturer provides antibody testing

data- <https://www.biolegend.com/de-de/products/trustain-fcx-anti-mouse-cd16-32-antibody-5683?GroupID=BLG9237>

Eukaryotic cell lines

Policy information about [cell lines and Sex and Gender in Research](#)

Cell line source(s)	mBA cell line was derived in house from control and knockout <i>Mus musculus</i> , from two animals pooled from each gender. HEK 293FT cells were procured commercially from Thermo Fischer Scientific, Cat No. R70007 (https://www.thermofisher.com/order/catalog/product/de/en/R70007).
Authentication	The cell lines were authenticated for their genotypes using western blotting. For 293FT cells, authentication data can be obtained from the manufacturer at the link - https://www.thermofisher.com/order/catalog/product/de/en/R70007
Mycoplasma contamination	The cell lines were routinely tested and confirmed negative for mycoplasma contamination
Commonly misidentified lines (See ICLAC register)	No ICLAC cell lines were used in the study

Animals and other research organisms

Policy information about [studies involving animals; ARRIVE guidelines](#) recommended for reporting animal research, and [Sex and Gender in Research](#)

Laboratory animals	The age of the mice used in this study ranged from 4 weeks to 22 weeks old and is specified in the legend.
Wild animals	The study did not involve wild animals
Reporting on sex	The tissue transcriptomics and proteomics findings apply only to male mice. All other in vivo experimental findings were performed on both genders and the data has been presented in a sex segregated manner, as indicated in figure legends. Where there is no mention, the sexes were selected in a randomized manner.
Field-collected samples	The study did not involve field collected animals
Ethics oversight	All animal procedures included in the study were conducted in accordance with European National and institutional guidelines and protocols were approved by local government authorities (Landesamt für Natur, Umwelt und Verbraucherschutz Nordrhein-Westfalen, Germany).

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Plants

Seed stocks	n/a
Novel plant genotypes	n/a
Authentication	n/a

ChIP-seq

Data deposition

- ☒ Confirm that both raw and final processed data have been deposited in a public database such as [GEO](#).
- ☒ Confirm that you have deposited or provided access to graph files (e.g. BED files) for the called peaks.

Data access links
May remain private before publication.

<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296541>

Files in database submission

A006200376_218434_S7_L001_R1_001.fastq.gz A006200376_218434_S7_L001_R2_001.fastq.gz
A006200376_218437_S8_L001_R1_001.fastq.gz A006200376_218437_S8_L001_R2_001.fastq.gz
A006200376_218439_S9_L001_R1_001.fastq.gz A006200376_218439_S9_L001_R2_001.fastq.gz
A006200376_218442_S10_L001_R1_001.fastq.gz A006200376_218442_S10_L001_R2_001.fastq.gz
A006200376_218444_S11_L001_R1_001.fastq.gz A006200376_218444_S11_L001_R2_001.fastq.gz
A006200376_218446_S12_L001_R1_001.fastq.gz A006200376_218446_S12_L001_R2_001.fastq.gz

A006200376_218448_S13_L001_R1_001.fastq.gz A006200376_218448_S13_L001_R2_001.fastq.gz
 A006200376_218450_S14_L001_R1_001.fastq.gz A006200376_218450_S14_L001_R2_001.fastq.gz
 A006200376_218452_S15_L001_R1_001.fastq.gz A006200376_218452_S15_L001_R2_001.fastq.gz
 A006200376_218454_S16_L001_R1_001.fastq.gz A006200376_218454_S16_L001_R2_001.fastq.gz
 A006200376_218456_S17_L001_R1_001.fastq.gz A006200376_218456_S17_L001_R2_001.fastq.gz
 A006200376_218458_S18_L001_R1_001.fastq.gz A006200376_218458_S18_L001_R2_001.fastq.gz
 A006200376_218468_S23_L001_R1_001.fastq.gz A006200376_218468_S23_L001_R2_001.fastq.gz
 A006200376_218470_S24_L001_R1_001.fastq.gz A006200376_218470_S24_L001_R2_001.fastq.gz
 A006200376_218472_S25_L001_R1_001.fastq.gz A006200376_218472_S25_L001_R2_001.fastq.gz
 WT-UT.narrowPeak
 WT-HG.narrowPeak
 KO-UT.narrowPeak

Genome browser session
 (e.g. [UCSC](#))

no longer applicable

Methodology

Replicates

4 replicates, per condition WT-UT, WT-HG, KO-UT

Sequencing depth

25 million reads

Antibodies

H3K4me3 (Active Motif, cat no:39159)

Peak calling parameters

Genrich -t
 A006200376_218434_S7_L001.sorted.bam,A006200376_218439_S9_L001.sorted.bam,A006200376_218437_S8_L001.sorted.bam,A
 006200376_218442_S10_L001.sorted.bam -c
 A006200376_218468_S23_L001.sorted.bam,A006200376_218468_S23_L001.sorted.bam,A006200376_218468_S23_L001.sorted.ba
 m,A006200376_218468_S23_L001.sorted.bam -o WT-UT.narrowPeak.bed -f WT-UT.bedgraph.log -R WT-UT.duplicates -b WT-
 UT_reads_fragments_intervals.bed -k WT-UT_pileups.bdgr -r -x -q 0.05 -a 20.0 -e
 chrX,chrY,chrM,GL456210.1,GL456211.1,GL456212.1,GL456213.1,GL456216.1,GL456219.1,GL456221.1,GL456233.1,GL456239.1,GL
 456350.1,GL456354.1,GL456359.1,GL456360.1,GL456366.1,GL456367.1,GL456368.1,GL456370.1,GL456372.1,GL456378.1,GL45637
 9.1,GL456381.1,GL456382.1,GL456383.1,GL456385.1,GL456387.1,GL456389.1,GL456390.1,GL456392.1,GL456393.1,GL456394.1,GL
 456396.1,JH584292.1,JH584293.1,JH584294.1,JH584295.1,JH584296.1,JH584297.1,JH584298.1,JH584299.1,JH584300.1,JH584301.1
 ,JH584302.1,JH584303.1,JH584304.1,chr1_GL456210v1_random,chr1_GL456211v1_random,chr1_GL456212v1_random,chr1_GL45
 6221v1_random,chr1_GL456239v1_random,chr1_MU069434v1_random,chr4_JH584295v1_random,chr5_GL456354v1_random,chr
 5_JH584296v1_random,chr5_JH584297v1_random,chr5_JH584298v1_random,chr5_JH584299v1_random,chr7_GL456219v1_rando
 m,chrM,chrUn_GL456359v1,chrUn_GL456360v1,chrUn_GL456366v1,chrUn_GL456367v1,chrUn_GL456368v1,chrUn_GL456370v1,c
 hrUn_GL456372v1,chrUn_GL456378v1,chrUn_GL456379v1,chrUn_GL456381v1,chrUn_GL456382v1,chrUn_GL456383v1,chrUn_GL4
 56385v1,chrUn_GL456387v1,chrUn_GL456389v1,chrUn_GL456390v1,chrUn_GL456392v1,chrUn_GL456394v1,chrUn_GL456396v1,c
 hrUn_JH584304v1,chrUn_MU069435v1,chrX_GL456233v2_random,chrY_JH584300v1_random,chrY_JH584301v1_random,chrY_JH5
 84302v1_random,chrY_JH584303v1_random -E /mnt/c/Users/trotos/Desktop/bwa/mm39.excluderanges.bed -v -z

Genrich -t
 A006200376_218444_S11_L001.sorted.bam,A006200376_218446_S12_L001.sorted.bam,A006200376_218448_S13_L001.sorted.ba
 m,A006200376_218450_S14_L001.sorted.bam -c
 A006200376_218470_S24_L001.sorted.bam,A006200376_218470_S24_L001.sorted.bam,A006200376_218470_S24_L001.sorted.ba
 m,A006200376_218470_S24_L001.sorted.bam -o WT-HG.narrowPeak.bed -f WT-HG.bedgraph.log -R WT-HG.duplicates -b WT-
 HG_reads_fragments_intervals.bed -k WT-HG_pileups.bdgr -r -x -q 0.05 -a 20.0 -e
 chrX,chrY,chrM,GL456210.1,GL456211.1,GL456212.1,GL456213.1,GL456216.1,GL456219.1,GL456221.1,GL456233.1,GL456239.1,GL
 456350.1,GL456354.1,GL456359.1,GL456360.1,GL456366.1,GL456367.1,GL456368.1,GL456370.1,GL456372.1,GL456378.1,GL45637
 9.1,GL456381.1,GL456382.1,GL456383.1,GL456385.1,GL456387.1,GL456389.1,GL456390.1,GL456392.1,GL456393.1,GL456394.1,GL
 456396.1,JH584292.1,JH584293.1,JH584294.1,JH584295.1,JH584296.1,JH584297.1,JH584298.1,JH584299.1,JH584300.1,JH584301.1
 ,JH584302.1,JH584303.1,JH584304.1,chr1_GL456210v1_random,chr1_GL456211v1_random,chr1_GL456212v1_random,chr1_GL45
 6221v1_random,chr1_GL456239v1_random,chr1_MU069434v1_random,chr4_JH584295v1_random,chr5_GL456354v1_random,chr
 5_JH584296v1_random,chr5_JH584297v1_random,chr5_JH584298v1_random,chr5_JH584299v1_random,chr7_GL456219v1_rando
 m,chrM,chrUn_GL456359v1,chrUn_GL456360v1,chrUn_GL456366v1,chrUn_GL456367v1,chrUn_GL456368v1,chrUn_GL456370v1,c
 hrUn_GL456372v1,chrUn_GL456378v1,chrUn_GL456379v1,chrUn_GL456381v1,chrUn_GL456382v1,chrUn_GL456383v1,chrUn_GL4
 56385v1,chrUn_GL456387v1,chrUn_GL456389v1,chrUn_GL456390v1,chrUn_GL456392v1,chrUn_GL456394v1,chrUn_GL456396v1,c
 hrUn_JH584304v1,chrUn_MU069435v1,chrX_GL456233v2_random,chrY_JH584300v1_random,chrY_JH584301v1_random,chrY_JH5
 84302v1_random,chrY_JH584303v1_random -E /mnt/c/Users/trotos/Desktop/bwa/mm39.excluderanges.bed -v -z

Genrich -t
 A006200376_218452_S15_L001.sorted.bam,A006200376_218454_S16_L001.sorted.bam,A006200376_218456_S17_L001.sorted.ba
 m,A006200376_218458_S18_L001.sorted.bam -c
 A006200376_218472_S25_L001.sorted.bam,A006200376_218472_S25_L001.sorted.bam,A006200376_218472_S25_L001.sorted.ba
 m,A006200376_218472_S25_L001.sorted.bam -o KO-UT.narrowPeak.bed -f KO-UT.bedgraph.log -R KO-UT.duplicates -b KO-
 UT_reads_fragments_intervals.bed -k KO-UT_pileups.bdgr -r -x -q 0.05 -a 20.0 -e
 chrX,chrY,chrM,GL456210.1,GL456211.1,GL456212.1,GL456213.1,GL456216.1,GL456219.1,GL456221.1,GL456233.1,GL456239.1,GL
 456350.1,GL456354.1,GL456359.1,GL456360.1,GL456366.1,GL456367.1,GL456368.1,GL456370.1,GL456372.1,GL456378.1,GL45637
 9.1,GL456381.1,GL456382.1,GL456383.1,GL456385.1,GL456387.1,GL456389.1,GL456390.1,GL456392.1,GL456393.1,GL456394.1,GL
 456396.1,JH584292.1,JH584293.1,JH584294.1,JH584295.1,JH584296.1,JH584297.1,JH584298.1,JH584299.1,JH584300.1,JH584301.1
 ,JH584302.1,JH584303.1,JH584304.1,chr1_GL456210v1_random,chr1_GL456211v1_random,chr1_GL456212v1_random,chr1_GL45
 6221v1_random,chr1_GL456239v1_random,chr1_MU069434v1_random,chr4_JH584295v1_random,chr5_GL456354v1_random,chr

5_JH584296v1_random,chr5_JH584297v1_random,chr5_JH584298v1_random,chr5_JH584299v1_random,chr7_GL456219v1_random,chrM,chrUn_GL456359v1,chrUn_GL456360v1,chrUn_GL456366v1,chrUn_GL456367v1,chrUn_GL456368v1,chrUn_GL456370v1,chrUn_GL456372v1,chrUn_GL456378v1,chrUn_GL456379v1,chrUn_GL456381v1,chrUn_GL456382v1,chrUn_GL456383v1,chrUn_GL456385v1,chrUn_GL456387v1,chrUn_GL456389v1,chrUn_GL456390v1,chrUn_GL456392v1,chrUn_GL456394v1,chrUn_GL456396v1,chrUn_JH584304v1,chrUn_MU069435v1,chrX_GL456233v2_random,chrY_JH584300v1_random,chrY_JH584301v1_random,chrY_JH584302v1_random,chrY_JH584303v1_random -E /mnt/c/Users/trotos/Desktop/bwa/mm39.excluderanges.bed -v -z

Data quality

Genrich called peaks for multiple replicates collectively. First, it analyzed the replicates separately, with p-values calculated for each. At each genomic position, the multiple replicates' p-values were then combined by Fisher's method. The combined p-values were converted to q-values, and peaks were called.

KO-UT peaks at FDR 0.05 15118 AUC 20

WT-HG peaks at FDR 0.05 14060 AUC 20

WT-UT peaks at FDR 0.05 12342 AUC 20

Software

We used the snakePipes pipeline the module for ChIP-seq. <https://github.com/maxplanck-ie/snakepipes>. Other softwares used during analysis were -

snakePipes version 2.8.1

deeptools version 3.5.4

samtools version 1.19.2

fastqc version 0.12.1

fastp version 0.23.4

genrich version 0.6.1

R version 4.4.2

bedtools version 2.31.0

Flow Cytometry

Plots

Confirm that:

- ☒ The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- ☒ The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
- ☐ All plots are contour plots with outliers or pseudocolor plots.
- ☒ A numerical value for number of cells or percentage (with statistics) is provided.

Methodology

Sample preparation

For single cell suspension, bone marrow was flushed with 10 ml of FACS buffer from the femur of adult mice using a 27 G needle and syringe through a 40 µm strainer. Brown adipose tissue was dissected and immediately transferred in ice-cold digesting solution. Tissues were cut in little pieces with scissors and incubated in digesting solution containing Collagenase IV (1 mg/ml), and DNase I (0.01 mg/ml) in RPMI for 40 min at 37°C in the shaker. Digestion was stopped by adding 10% FBS on ice. Tissue homogenates were smashed and washed with FACS buffer against a 70 µm strainer using the back of a syringe. Pellets were resuspended in 1 ml red blood cell lysis buffer (Roche) and incubated for 10 min at RT for lysis of erythrocytes. Subsequently, 10 ml FACS buffer (5% FCS in PBS) was added and cells were centrifuged at 300 g for 5 min at 4°C. The cells were pre-incubated with fix viability dye in PBS (1:1000) for 10 min at RT, for BAT a mix of anti-mouse FcγRII/III receptor (CD16/CD32)-blocking antibodies (1:500) was added. After wash with FACS buffer, cells were stained with the fluorochrome-conjugated antibodies (1:100 0.25–1 µg; listed below). Only BAT cells were fixed and permeabilized with FoxP3 kit according to manufacturer instructions, and then incubated with iNOS and Arg-1 antibodies 20 min at RT for intracellular staining.

Instrument

FACS Symphony™ A3 flow cytometer (BD)

Software

Acquisition software: Diva software (BD) . Analysis software: FlowJo version 10.0.8, LLC.

Cell population abundance

For absolute quantification, 25 µL of counting beads (at a concentration of 1,000 beads/µL) were added to 250 µL of single-cell suspension. After gating, the absolute number of cells (cells/µL) was determined using the following equation:

$$\text{Absolute count (cells/}\mu\text{L)} = (\text{Cell count} \times \text{Counting beads volume}) / (\text{Counting bead count} \times \text{Sample volume}) \times \text{Counting bead concentration}.$$

Each population was expressed in absolute numbers (cells/µL), and results were further normalized to the initial tissue weight (grams of BAT) for comparison across samples.

Gating strategy

For both brown adipose tissue (BAT) and bone marrow, the gating strategy begins with the selection of single cells by excluding doublets, ensuring that only individual cellular events are analyzed. Live immune cells are then identified by gating for CD45-positive cells that are negative for the viability dye, thereby excluding dead cells and non-immune populations from further analysis. To focus on progenitor populations, mature lymphoid and myeloid cells are excluded using a lineage (Lin) cocktail containing markers for erythrocytes, B cells, T cells, and NK cells. Specifically, the Lin cocktail includes Ter119 (erythrocytes), CD19 and B220 (B cells), CD49b and NK1.1 (NK cells and some T cell subsets), and CD3e (T cells)
 Subpopulation in BAT:
 Myeloid cells are then selected by gating on CD172a-positive cells and Lin-negative. Subsequent gating steps use lineage-

specific markers to further resolve myeloid subpopulations: macrophages are identified as F4/80-positive, CD11b-positive cells, while dendritic cells are defined as F4/80-negative, MHCII-positive, CD11c-positive cells. Macrophage subsets are then distinguished based on Ly6C expression, with F4/80-positive, Ly6C^{hi} cells representing pro-inflammatory macrophages, and F4/80-positive, Ly6C^{lo} cells representing anti-inflammatory macrophages.

Subpopulation in Bone Marrow:

Lymphoid progenitors are identified as CD127-positive, Lin-negative cells, while myeloid progenitors are CD127-negative, Lin-negative. Within these populations, further markers are used to distinguish specific progenitor subsets:

- Common lymphoid progenitors (CLP): CD127⁺, Lin⁻, CD117^{int/low}, Sca-1⁺
- Monocyte/dendritic cell progenitors (MDP): CD127⁻, Lin⁻, CD115⁺, CD117⁺, CD135⁺
- Common monocyte progenitors (cMoP): CD127⁻, Lin⁻, CD115⁺, CD117⁺, CD135⁻
- Monocytes: CD127⁻, Lin⁻, CD115⁺, CD117⁻, CD135⁻
- Hematopoietic stem and progenitor cells (HSPC): CD127⁻, Lin⁻, CD117⁺, Sca-1⁺
- HSPC subsets:
 - Granulocyte-monocyte progenitors (GMP): CD16/32⁺, CD34⁺
 - Megakaryocyte-erythroid progenitors (MEP): CD16/32⁻, CD34⁻
 - Common myeloid progenitors (CMP): CD16/32⁻, CD34⁺

☒ Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.